subject.id,manuscript.id,arm,treatment,tumor.type,panel.id,timepoint.id,cell.population.name,percent.of.parent,best.overall.response,responder.flag.crpr,disease.control.flag,cd8.converter.flag
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD3,16.15687175,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD3 | KI67,2.6593063,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD56,0.0674305225,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD8,7.853444,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD8 | KI67,2.4697714499999996,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,FOXP3,0.25512875,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,Tumor,32.95788,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,Tumor | KI67,9.0781135,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,CD3,17.521563999999998,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,CD3 | KI67,3.2663132,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,CD56,0.032981532,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,CD8,19.710829500000003,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,CD8 | KI67,1.57242755,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,FOXP3,0.027165658500000002,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,Tumor,32.979710499999996,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,On-Treatment,Tumor | KI67,5.943115799999999,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20,10.4822643,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | CD80,3.444031,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | INOS,34.037133,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | PDL1,29.899411,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,11.31771,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68,6.3742275,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | CD80,1.188919,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | INOS,10.191068300000001,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | PDL1,26.393464,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,4.893321,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD80,5.281194299999999,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,INOS,26.398787,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,PDL1,27.087769,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,Tumor,27.074696499999998,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,Tumor | PDL1,46.8127075,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD20,19.271071,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD20 | CD80,2.5280898,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD20 | INOS,36.797753,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD20 | PDL1,10.714286000000001,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD20 | PDL1*INOS,3.678161,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD68,4.0625,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD68 | CD80,0,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD68 | INOS,3.8461540000000003,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD68 | PDL1,32.692307,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD68 | PDL1*INOS,1.4084507,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,CD80,6.832544,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,INOS,28.018817000000002,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,PDL1,15.225643,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,Tumor,31.621002999999998,NA,N,N,N
101-0001,001,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,On-Treatment,Tumor | PDL1,26.06438,NA,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,11.5455345,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,0.1369863,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,0.700401075,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,36.508533,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,0.599796175,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3,31.240114999999996,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3 | KI67,0.1633987,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD56,0.027100270000000003,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8,2.9277478500000003,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8 | KI67,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,FOXP3,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor,37.00332,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor | KI67,0.227354455,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,9.0238265,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,7.1316615,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,44.9828475,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,45.3687835,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,4.6663444499999995,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,6.308654349999999,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,2.9411765,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,18.2067245,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,1.47058825,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,2.57118505,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,33.3406425,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,23.105256500000003,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,24.9209405,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,36.091745,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20,2.0505043499999998,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | CD80,14.7222223,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | INOS,12.5,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1,50.138889500000005,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68,7.0447335,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | CD80,23.333333500000002,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | INOS,5,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1,38.095239,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,3,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD80,4.302908,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,INOS,0.7924587000000001,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,PDL1,42.391976,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor,11.47116425,Progressive Disease,N,N,N
101-0003,002,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor | PDL1,71.318485,Progressive Disease,N,N,N
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD3,7.7159144,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD3 | KI67,0.56818184,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD56,3.6149092,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD8,6.2471077,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD8 | KI67,0.37037035999999995,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,FOXP3,2.4550635,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,Tumor,37.591308,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,Tumor | KI67,33.981066999999996,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD20,1.828228575,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD20 | CD80,20.8390335,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD20 | INOS,3.79616965,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD20 | PDL1,22.5661183,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD20 | PDL1*INOS,1.5104879,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD68,10.101605300000001,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD68 | CD80,67.883085,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD68 | INOS,8.4493602,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD68 | PDL1,75.198058,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD68 | PDL1*INOS,7.3281305,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,CD80,28.1239115,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,INOS,11.91560725,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,PDL1,22.813406,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,Tumor,31.524423,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel B,Baseline,Tumor | PDL1,17.82864225,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4,7.225034399999999,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1,5.732484,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1*TCF1/7,0.6960557,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1*TOX,1.476696,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | TCF1/7,5.172414,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | TOX,4.054054,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD68/CD163,5.5223192999999995,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD68/CD163 | PD1,0.4484305,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8,4.467169,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1,8.045977,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1*TOX,1.2048192,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | TCF1/7,2.6785715000000003,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | TOX,32.515338,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,PD1,2.1085514,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,TCF1/7,0.7534984,Progressive Disease,N,N,NA
101-0004,003,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,TOX,15.232398,Progressive Disease,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3,25.445764999999998,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3 | KI67,4.047054849999999,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD56,14.131434500000001,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8,11.60838155,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8 | KI67,1.75,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,FOXP3,4.840315,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor,17.2483735,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor | KI67,14.680199,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20,5.3309295,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | CD80,2.4793388,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | INOS,10.174418000000001,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1,4.5454547,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.29069767,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68,22.203462,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | CD80,0.48879837,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | INOS,33.460075,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1,8.197989,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.4640371,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD80,1.3988756999999998,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,INOS,21.042635,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,PDL1,3.3608034,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor,1.5407345,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor | PDL1,0.57803467,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4,25.580363,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1,21.067785,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,7.7492445,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TOX,0.502366145,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TCF1/7,20.489779,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TOX,3.88778095,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163,9.8812989999999985,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163 | PD1,18.7860595,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8,2.5217987500000003,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1,10.3456615,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,3.2145919500000004,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TOX,0.7075472,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TCF1/7,25.765652000000003,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TOX,5.7813651,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,PD1,25.583538,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TCF1/7,12.4103025,NA,N,N,NA
101-0005,004,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TOX,3.5543195999999995,NA,N,N,NA
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD3,3.7185356,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD3 | KI67,10.769231,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD56,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD8,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,CD8 | KI67,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,FOXP3,1.1441648,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,Tumor,21.567506,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel A,Baseline,Tumor | KI67,5.30504,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20,18.569710999999998,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | INOS,8.0906145,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | PDL1,11.0032365,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,0.6472492,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68,1.2019231,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | CD80,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | PDL1,75,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,CD80,0.8413462,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,INOS,7.5120196,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,PDL1,22.35577,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,Tumor,38.701921999999996,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel B,Baseline,Tumor | PDL1,42.391303,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4,14.060357000000002,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4 | PD1,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4 | TCF1/7,0.4878049,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD4 | TOX,33.658537,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD68/CD163,22.976679999999998,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD68/CD163 | PD1,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8,10.2194786,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8 | PD1,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8 | PD1*TOX,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8 | TCF1/7,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,CD8 | TOX,23.489933,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,PD1,0,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,TCF1/7,0.27434842000000004,Progressive Disease,N,N,Y
101-0006,005,CD8 LOW,Nivolumab + Ipilimumab,Pancreatic carcinoma,Panel C,Baseline,TOX,43.415639999999996,Progressive Disease,N,N,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD3,12.764633,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD3 | KI67,0.24390244,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD56,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD8,23.132005,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD8 | KI67,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,FOXP3,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,Tumor,33.437112,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,Tumor | KI67,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,CD3,28.04854,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,CD3 | KI67,13.771996999999999,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,CD56,0.00668628,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,CD8,23.335116,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,CD8 | KI67,6.2451813000000005,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,FOXP3,0.9417378000000001,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,Tumor,26.268207999999998,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,On-Treatment,Tumor | KI67,4.3385489999999995,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20,0.138408325,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | CD80,25,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | INOS,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | PDL1,44.23077,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68,3.28702235,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | CD80,1.4188495250000002,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | INOS,5.001284,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | PDL1,86.985473,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | PDL1*INOS,4.340010299999999,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD80,12.0914975,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,INOS,4.4691209,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,PDL1,28.816747499999998,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,Tumor,31.748749000000004,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,Tumor | PDL1,32.640051,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD20,3.0555556,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD20 | CD80,13.397129,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD20 | INOS,4.5454547,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD20 | PDL1,84.347826,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,1.4354067,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD68,9.527458,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD68 | CD80,9.892473,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD68 | INOS,19.57672,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD68 | PDL1,60.052910000000004,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,4.895105,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,CD80,18.171965,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,INOS,29.683346,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,PDL1,30.127641999999998,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,Tumor,20.522118,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,On-Treatment,Tumor | PDL1,7.692308000000001,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4,0.31910649999999996,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1,4.1666668,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | TCF1/7,18.75,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | TOX,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD68/CD163,6.990622,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD68/CD163 | PD1,14.189189999999998,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8,34.314879999999995,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1,19.450802,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1*TOX,18.993135,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | TCF1/7,0.20802186,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | TOX,62.700230000000005,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,PD1,9.462112000000001,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,TCF1/7,0.10389609999999999,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,TOX,39.615235,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4,13.1132375,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4 | PD1,19.212094999999998,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.1374407,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4 | PD1*TOX,2.62080385,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4 | TCF1/7,10.3373295,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD4 | TOX,8.318173999999999,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD68/CD163,25.859513,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD68/CD163 | PD1,13.674470500000002,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8,15.504354,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8 | PD1,22.630138000000002,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.42462847000000004,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8 | PD1*TOX,5.5494875,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8 | TCF1/7,6.6905482,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,CD8 | TOX,13.516184,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,PD1,14.4233755,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,TCF1/7,3.0684666500000004,Partial Response,Y,Y,Y
101-0007,006,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,On-Treatment,TOX,30.4677515,Partial Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3,28.16802,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,10.6516294,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD56,0.25325615,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8,8.339362999999999,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,12.5,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,FOXP3,2.5868306,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor,19.381107,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,11.5485564,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3,27.248493,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3 | KI67,7.537687999999999,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD56,0.09376465,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8,25.194020000000002,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8 | KI67,7.9489,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,FOXP3,3.5024155,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor,11.884383,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor | KI67,6.990014,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20,7.96055135,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,11.401471500000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,19.2605505,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,24.923692000000003,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,2.0011411,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68,9.9346893,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,32.638654,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,36.729028,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,59.65311,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,19.817075,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD80,27.877679999999998,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,INOS,31.5089345,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,PDL1,23.2884825,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor,31.425124500000003,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,14.6840015,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20,16.76409,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | CD80,17.081552000000002,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | INOS,9.8855595,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1,18.228624,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0.8273202,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68,10.1276005,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | CD80,29.587632499999998,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | INOS,17.49226,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1,62.97921650000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,3.99377115,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD80,26.505958999999997,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,INOS,23.509190500000003,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,PDL1,29.749274,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor,11.18414975,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor | PDL1,30.933445499999998,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4,10.291535,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,7.508533000000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.3651877,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,3.7542664000000006,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,11.604095000000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,14.102565,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,20.588236,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,3.1141868,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8,9.065301,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,23.243243,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.33557047,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,15.135135,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,4.0358745,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,35.57047,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,PD1,5.4092027,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TCF1/7,7.351974,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TOX,18.897085,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4,17.058297,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1,14.806201999999999,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,2.0833334,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TOX,6.796116400000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TCF1/7,20.819491,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TOX,29.166666000000003,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163,23.156951,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163 | PD1,12.474438000000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8,19.807506999999998,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1,11.523688,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.22646223499999998,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TOX,2.946593,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TCF1/7,4.63353,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TOX,15.561694000000001,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,PD1,12.993262999999999,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TCF1/7,6.6351569999999995,Complete Response,Y,Y,Y
101-0008,007,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TOX,14.952204,Complete Response,Y,Y,Y
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3,9.645260500000001,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3 | KI67,1.7543860000000002,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD56,0.058616645,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8,1.5603927499999999,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8 | KI67,2.9411765,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,FOXP3,0.25425426,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor,44.9419725,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor | KI67,0.84516067,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20,2.6455026,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | CD80,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | INOS,41.176469999999995,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1,97.64706,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1*INOS,41.176469999999995,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68,0.5291005,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | INOS,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1,12.5,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD80,0.26455026,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,INOS,3.3068783999999996,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,PDL1,13.440861000000002,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor,42.49012,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor | PDL1,0.22573364,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4,5.8618285,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4 | PD1,0.5952381,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4 | TCF1/7,11.904762,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD4 | TOX,2.3809524,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD68/CD163,7.266436,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD68/CD163 | PD1,17.142858,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8,1.2403100999999999,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8 | PD1,12.5,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8 | PD1*TOX,7.7943615,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8 | TCF1/7,0,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,CD8 | TOX,14.738806,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,PD1,8.8693954,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,TCF1/7,1.4992503000000001,Partial Response,Y,Y,NA
101-0010,008,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel C,Baseline,TOX,16.569200000000002,Partial Response,Y,Y,NA
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3,8.2967415,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3 | KI67,0.6048387,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD56,0.0231107,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8,4.29859,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8 | KI67,0.5376344,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,FOXP3,0.44315400000000005,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor,29.898989999999998,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor | KI67,5.116279,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,CD3,6.7789835,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,CD3 | KI67,4.1314019,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,CD56,0.10987232499999999,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,CD8,5.7205094,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,CD8 | KI67,3.8717058499999997,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,FOXP3,0.285345585,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,Tumor,32.866521,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,On-Treatment,Tumor | KI67,9.97620375,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20,8.596250699999999,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | CD80,0.23584906000000003,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1,2.19518815,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68,2.4207391,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | CD80,1.3100437,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | INOS,1.78571435,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1,37.381032,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1*INOS,1.78571435,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD80,0.550042865,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,INOS,0.363209965,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,PDL1,18.724629999999998,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor,29.72551,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor | PDL1,39.76750200000001,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD20,3.70661725,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD20 | CD80,1.0526316,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD20 | INOS,0.18726592,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD20 | PDL1,7.75853125,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD68,0.78633145,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD68 | CD80,1,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD68 | INOS,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD68 | PDL1,51.75,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,CD80,0.2967664,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,INOS,0.08629363400000001,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,PDL1,27.889398,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,Tumor,34.0451415,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,On-Treatment,Tumor | PDL1,47.487451,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4,7.833733,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1,0.6993007,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TOX,0.44247786999999994,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TCF1/7,3.9577837999999996,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TOX,11.734694,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163,24.352086,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163 | PD1,3.2608695,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8,5.6354918,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1,0.17391304999999999,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TOX,0.17391304999999999,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TCF1/7,2.4347827,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TOX,26.241135999999997,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,PD1,0.837521,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TCF1/7,4.5115170000000004,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TOX,21.810961000000002,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4,1.4722326000000001,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4 | PD1,0.8547009,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.8196721,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4 | TCF1/7,2.5316456,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD4 | TOX,53.16456000000001,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD68/CD163,8.106597,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD68/CD163 | PD1,0.71123755,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8,3.0162843,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8 | PD1,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8 | PD1*TOX,0,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8 | TCF1/7,1.8404908000000002,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,CD8 | TOX,27.941176000000002,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,PD1,0.10337698,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,TCF1/7,1.0105581000000001,Progressive Disease,N,N,N
101-0011,009,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,On-Treatment,TOX,36.58401,Progressive Disease,N,N,N
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3,3.5353534,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3 | KI67,21.428572000000003,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD56,2.5252525,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8,2.2727273,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8 | KI67,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,FOXP3,1.7676767,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor,2.0202020000000003,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor | KI67,12.5,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20,6.412826000000001,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | CD80,40.625,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | INOS,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68,10.621242,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | CD80,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | INOS,1.8867925,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD80,2.6052104,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,INOS,2.6052104,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,PDL1,0,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor,1.2024048,Progressive Disease,N,N,Y
101-0013,010,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor | PDL1,0,Progressive Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3,7.249071,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,5.1282052,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD56,6.1338289999999995,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8,4.784689,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,4.6875,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,FOXP3,2.1291867,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor,28.491768,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,17.214532,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3,21.635884,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3 | KI67,6.910569,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD56,6.363307,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8,10.21461,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8 | KI67,6.89013,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,FOXP3,3.7023593,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor,25.112012,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor | KI67,16.990641,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20,1.8930959,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,31.428573,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,3.3898304999999995,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,9.523810000000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68,9.090909,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,34.48276,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,8.585858,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,1.8034952,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.56818185,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD80,11.1793615,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,INOS,13.513513,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,PDL1,3.1746034,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor,27.950644000000004,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,2.2422134000000002,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20,2.2183558,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | CD80,19.520547999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | INOS,4.195804,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1,39.869282,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,1.8518519,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68,14.413825999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | CD80,22.058823999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | INOS,9.645131999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1,40.734263999999996,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,5.186533,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD80,10.435349500000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,INOS,13.499632,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,PDL1,28.620988000000004,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor,23.575467,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor | PDL1,7.438551,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4,19.103223,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,4.5454547,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.17152659,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,0.113425955,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,1.0460251,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,0.62761507,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,18.962536999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,1.2135922000000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8,18.012422,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,6.401138,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.23743841999999998,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,1.8492176999999999,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,1.4906832,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,56.024843000000004,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,PD1,4.1234568,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TCF1/7,1.7880224,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TOX,13.70099,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4,10.446444000000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1,7.038123000000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.6430868000000001,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.16891892,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TCF1/7,1.4141821,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TOX,1.8018018,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163,18.545967,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163 | PD1,2.909091,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8,8.4422655,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1,9.0243906,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.1985209,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TOX,4.3165468,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TCF1/7,1.3601708500000003,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TOX,54.44126,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,PD1,9.204793,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TCF1/7,0.3101737,Stable Disease,N,N,Y
101-0015,011,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TOX,15.290102,Stable Disease,N,N,Y
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,CD3,15.890954,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,6.32936535,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,CD56,1.4344223500000002,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,CD8,7.052231,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,8.352851300000001,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,FOXP3,4.37376815,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,Tumor,46.7679395,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,15.2744635,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,CD3,23.99302,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,CD3 | KI67,12.130177999999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,CD56,1.0091302,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,CD8,14.797864999999998,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,CD8 | KI67,15.141957,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,FOXP3,8.602419,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,Tumor,25.443295,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel A,On-Treatment,Tumor | KI67,8.6419754,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD20,2.9656364,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,39.106146,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,4.6455026,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,42.60355,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,1.3043478000000002,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD68,8.219178000000001,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,74.08585,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,37.39496,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,59.243697,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,13.690475999999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,CD80,27.28867,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,INOS,32.1327,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,PDL1,33.281028,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,Tumor,25.02746,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,30.532786,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD20,7.1829195,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD20 | CD80,23.1320765,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD20 | INOS,7.0355395000000005,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1,27.958758,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,2.7525252499999997,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD68,6.742484000000001,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD68 | CD80,57.188935,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD68 | INOS,8.221917999999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1,81.5985945,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,6.6507,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,CD80,29.051414,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,INOS,26.910259,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,PDL1,34.180972,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,Tumor,21.385338,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel B,On-Treatment,Tumor | PDL1,7.438674499999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4,1.4923672,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,2.2727273,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,0.34662044999999997,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,3.1347964,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,4.674214749999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,8.268753,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,4.8360353,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8,8.279962,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,5.0626774,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.167504185,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,2.7275644999999997,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,4.5454547,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,54.82143,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,PD1,14.3518375,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,TCF1/7,0.49401480000000003,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,Baseline,TOX,16.2073935,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4,15.018816,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1,4.0404040000000006,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.44990248499999996,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.0872921500000001,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TCF1/7,10.933940999999999,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TOX,17.312072,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163,9.5098324,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163 | PD1,7.349081,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8,4.9244545,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1,17.845118,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,1.3714715,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TOX,9.6969694,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TCF1/7,20.133305999999997,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TOX,39.007092,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,PD1,18.444924,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,TCF1/7,4.2679238,Stable Disease,N,N,NA
101-0017,073,CD8 HIGH,Nivolumab,Ovarian cancer,Panel C,On-Treatment,TOX,21.723835,Stable Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD3,8.9254657,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD3 | KI67,0.763102655,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD56,3.3635916000000003,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD8,5.828671249999999,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,CD8 | KI67,2.2988505999999997,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,FOXP3,1.5117350000000003,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,Tumor,28.0113375,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel A,Baseline,Tumor | KI67,4.66923605,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20,8.556949999999999,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | CD80,54.940358,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | INOS,0.04553734,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | PDL1,54.531561999999994,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68,4.889115500000001,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | CD80,44.074075,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | PDL1,48.271414500000006,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,CD80,23.587926500000002,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,INOS,1.9620361000000002,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,PDL1,20.073425999999998,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,Tumor,25.3883205,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel B,Baseline,Tumor | PDL1,10.652883500000002,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4,10.839859,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1,20.9375,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | PD1*TOX,1.0207153,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | TCF1/7,3.8243625000000003,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD4 | TOX,2.3867971,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD68/CD163,13.004760000000001,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD68/CD163 | PD1,6.122449,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8,23.213638,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1,22.586873,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.56818184,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | PD1*TOX,3.8610037,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | TCF1/7,5,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,CD8 | TOX,19.498070000000002,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,PD1,24.882118000000002,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,TCF1/7,1.8543957,Progressive Disease,N,N,NA
101-0019,012,CD8 LOW,Nivolumab + Ipilimumab,Non-small cell lung cancer,Panel C,Baseline,TOX,17.376374,Progressive Disease,N,N,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3,19.5446345,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,7.9791893,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD56,3.6865929,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8,7.403098249999999,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,10.766979,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,FOXP3,3.9634168,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor,33.902919999999995,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,18.510476500000003,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20,5.821168,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,23.636363,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,8.955224000000001,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,21.943573999999998,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.72492166,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68,4.1481733,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,51.282054,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,4.3137256,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,87.76042,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,3.1413610000000003,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD80,18.580376,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,INOS,17.211328,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,PDL1,25.780683999999997,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor,33.64929,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,5.4776218000000005,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4,1.7245192,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,4.1450776000000005,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.0362694000000001,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,2.5906736,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,5.5555556,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,11.111111,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,10.8114086,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,10.9947644,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8,2.3214681,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,6.6666669999999995,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,5.755396,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,3.3653848,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,87.5,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,PD1,20.239137,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TCF1/7,0.30952905999999997,Partial Response,Y,Y,NA
101-0020,013,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TOX,17.2673,Partial Response,Y,Y,NA
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,12.51414575,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,1.8706801,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,0.605340265,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,8.5226753,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,1.6067147999999998,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,0.49541118,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,19.2588265,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,3.698827275,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3,17.233684500000003,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3 | KI67,4.1916337,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD56,0.25864061,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8,18.508540500000002,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8 | KI67,3.388247,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,FOXP3,1.4359367,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor,16.768266,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor | KI67,3.29266115,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,8.1993485,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,0.22988506,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,0.8183305999999999,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,8.600387000000001,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,0.14880953,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,2.2693889499999997,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,2.27272735,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,4.304921650000001,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,19.145470000000003,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,1.4925373,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,0.10472147500000001,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,1.38650905,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,14.5294885,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,28.31119,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,30.54188,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20,0.36737078,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | CD80,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | INOS,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1,19.148937,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68,11.371094,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | CD80,0.12547051,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | INOS,0.10548523000000001,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1,33.656715999999996,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD80,0.055782817,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,INOS,0.023436888000000003,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,PDL1,15.546463,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor,19.403124,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor | PDL1,11.403929399999999,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4,4.6640944,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1,3.6697246000000003,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0.13351135,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TOX,0.9174311500000001,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TCF1/7,16.119403,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TOX,22.916667,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163,25.068089999999998,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163 | PD1,9.315455,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8,12.1100016,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1,0.30549897,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TOX,0.12820513,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TCF1/7,10.512821,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TOX,11.238095,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,PD1,2.2542682000000003,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TCF1/7,5.12183,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TOX,11.120708,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4,8.172332,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1,7.063572,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.37926675000000004,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TOX,3.539823,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TCF1/7,9.687184499999999,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TOX,19.599427,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163,26.938266,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163 | PD1,5.8114037,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8,23.703703,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1,16.885965,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TOX,6.5746754,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TCF1/7,1.1431412,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TOX,18.068834,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,PD1,7.971586,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TCF1/7,2.7784608,Stable Disease,N,N,Y
102-0013,018,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TOX,10.024049999999999,Stable Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,19.728293,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,0.5610098,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,0.12132240999999999,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,13.880685000000001,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,0.32751092,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,0.05967774,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,16.597755,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,10.1265825,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3,13.493063999999999,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3 | KI67,4.752066,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD56,0.8070617999999999,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8,11.387344,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8 | KI67,2.0997375,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,FOXP3,3.4336783000000004,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor,25.413147000000002,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor | KI67,13.559321999999998,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,0.30395137,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,35.9955,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,8.922792,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,0.63849575,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,2.3166023,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,40.932643,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,0.06500542000000001,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,0.057372346,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,49.46833,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,28.651488000000004,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,75.68437999999999,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20,0.1061866025,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | CD80,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1,20,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68,4.9489377,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | CD80,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1,42.886844499999995,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD80,0.01783803,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,INOS,0.05351409,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,PDL1,16.98272,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor,30.624695000000003,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor | PDL1,28.986581,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4,0.23084027000000001,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TCF1/7,18.181818999999997,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TOX,33.333334,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163,34.792715,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163 | PD1,2.8213166000000003,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8,6.2886596,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1,0.5074923,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TOX,0.1953125,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TCF1/7,1.1235955,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TOX,86.885244,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,PD1,0.7912687999999999,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TCF1/7,0.1780944,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TOX,46.0374,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4,7.8132365,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1,0.89869285,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TOX,0.6451613,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TCF1/7,4.173805,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TOX,15.7261115,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163,32.7834615,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163 | PD1,0.559345225,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8,23.540729,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1,0.08130081,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TOX,0,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TCF1/7,1.44125405,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TOX,14.602640999999998,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,PD1,0.240551155,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TCF1/7,1.207579425,Progressive Disease,N,N,Y
102-0016,020,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TOX,5.930430250000001,Progressive Disease,N,N,Y
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,3.1761096999999996,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,3.2582582999999996,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,53.250751,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,1.854354285,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,1.178678685,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,3.390950275,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,0.7739938,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,62.0623985,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,1.9426393499999999,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.7739938,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,2.333978763,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,16.5165995,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,24.054575,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,25.92559,NA,N,N,NA
102-0017,021,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,81.035673,NA,N,N,NA
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,1.534619625,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,3.2258065,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,0.061766524999999996,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,4.26873125,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.3345035,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,8.81560575,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,3.940281,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3,12.4947202,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3 | KI67,5.2601154999999995,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD56,0.27636459999999996,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8,20.4869735,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8 | KI67,2.4634333500000003,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,FOXP3,0.9091433800000002,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor,11.7452012,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor | KI67,5.023548,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,0.05249344,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,3.3112308500000003,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,1.5151516,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,9.84848505,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,12.3737375,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,19.89159,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,26.8317455,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,1.2033550000000002,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,18.796719500000002,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.6472492,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20,0.40248634,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | CD80,6.79723525,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | INOS,9.677419,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1,25.652842,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68,20.4142795,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | CD80,4.6808597,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | INOS,9.5862605,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1,33.6609465,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,1.2167130700000002,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD80,26.554244500000003,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,INOS,19.4119155,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,PDL1,15.058299,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor,11.627336849999999,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor | PDL1,3.95988475,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,0.401066735,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,1.5625,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,1.5625,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,1.5625,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,33.333334,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,12.181787499999999,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,15.5935615,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,5.87730665,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,0,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,0.27932959999999996,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,57.69231,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,2.2934113,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,0.22062878000000002,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,35.366544000000005,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4,9.256954499999999,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1,18.7334185,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.6756617249999999,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TOX,12.4367957,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TCF1/7,5.56863955,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TOX,50.069446,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163,34.9565935,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163 | PD1,16.474114,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8,9.7251655,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1,1.862771125,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.6849315,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TOX,0.33726813,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TCF1/7,7.793550250000001,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TOX,13.376469499999999,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,PD1,18.070093,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TCF1/7,5.14981785,Progressive Disease,N,N,Y
102-0019,023,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TOX,24.693373,Progressive Disease,N,N,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD3,4.538376,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD3 | KI67,1.47058825,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD56,0.37888032,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD8,3.75651185,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD8 | KI67,1.25,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,FOXP3,0.567297,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,Tumor,23.071617,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,Tumor | KI67,13.276822499999998,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20,31.840286000000003,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | CD80,0.16077170000000002,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | INOS,6.1897106,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1,28.938907000000004,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.08038585000000001,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68,4.2999744,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | INOS,0.5952381,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1,16.666667,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD80,0.9726132000000001,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,INOS,4.3255694,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,PDL1,11.159457,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor,54.568720000000006,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor | PDL1,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4,0.5105762300000001,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1,4.7619050000000005,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TOX,4.7619050000000005,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TCF1/7,4.7619050000000005,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TOX,38.095240000000004,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163,26.306832000000004,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163 | PD1,4.436229,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8,19.572088,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1,0.9937888,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TOX,0.7453416,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TCF1/7,0,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TOX,53.664595000000006,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,PD1,1.6289813,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TCF1/7,0.316071,Partial Response,Y,Y,Y
102-0021,024,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TOX,47.19183,Partial Response,Y,Y,Y
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,16.690442,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,5.6985293,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,3.169935,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,18.398692999999998,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,6.766917599999999,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,6.503299,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,19.901961,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,6.1764706,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,2.9268293,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,4.423077,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,5.5793993,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,45.49356,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.498683195,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,24.765691,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,6.012658399999999,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,16.925734000000002,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,49.275362,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,2.5906736,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,18.943483,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,25.703564,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,24.085365,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,16.071427999999997,Stable Disease,N,N,NA
102-0024,026,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,5.5,Stable Disease,N,N,NA
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20,0.049751246,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | PDL1,50,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68,1.6500218,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | CD80,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | PDL1,8.695651999999999,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD80,0.024875623,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,INOS,0.041811141,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,PDL1,35.472637,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,Tumor,33.36793,Progressive Disease,N,N,N
102-0025,027,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,Tumor | PDL1,72.35222,Progressive Disease,N,N,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,CD3,1.8656716,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,CD3 | KI67,6.329114,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,CD56,0.06472491699999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,CD8,3.0283911,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,CD8 | KI67,8.737864,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,FOXP3,0.34448819,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,Tumor,22.035140000000002,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,On-Treatment,Tumor | KI67,11.405835,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20,0.05221932,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | CD80,50,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | INOS,100,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1,100,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1*INOS,100,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68,0.31331594,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | INOS,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1,41.666666,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD80,0.49608354000000005,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,INOS,0.07832898399999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,PDL1,7.284595,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor,7.3107050000000005,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor | PDL1,63.57142999999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD20,2.1869044499999997,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD20 | CD80,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD20 | INOS,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD20 | PDL1,75.570668,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD68,0.8171339500000001,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD68 | CD80,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD68 | INOS,0.9803921999999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD68 | PDL1,70.07597999999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,CD80,0.03603597,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,INOS,0.17091652999999998,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,PDL1,16.6293395,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,Tumor,22.515855000000002,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,On-Treatment,Tumor | PDL1,39.0086685,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4,1.13059646,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TCF1/7,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TOX,5.263158,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163,1.4707325,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163 | PD1,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8,5.388427350000001,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1,0.13736264,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TOX,0,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TCF1/7,33.836997,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TOX,38.3241775,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,PD1,0.013605442499999999,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TCF1/7,7.663898,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TOX,20.1950245,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4,3.31931785,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4 | PD1,10.634921,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.1363637,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4 | PD1*TOX,3.6093075,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4 | TCF1/7,16.2128035,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD4 | TOX,20.677820500000003,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD68/CD163,9.971215,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD68/CD163 | PD1,0.790169785,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8,4.3127285,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8 | PD1,1.3015096000000002,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.304878035,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8 | PD1*TOX,0.692474935,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8 | TCF1/7,2.05934295,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,CD8 | TOX,16.0309925,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,PD1,0.8156746,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,TCF1/7,2.84081755,Partial Response,Y,Y,N
102-0027,029,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,On-Treatment,TOX,16.4349055,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3,0.09781037000000001,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3 | KI67,3.1688438000000003,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD56,5.21692075,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8,5.0602920000000005,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8 | KI67,5.4549964,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,FOXP3,0.18684573499999999,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor,36.3319875,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor | KI67,3.16664015,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,CD3,2.8344402,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,CD3 | KI67,2.5104603,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,CD56,0.058633833999999996,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,CD8,12.2292995,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,CD8 | KI67,1.4745308000000001,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,FOXP3,0.17590149,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,Tumor,23.529412,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,On-Treatment,Tumor | KI67,0.8683068,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20,0.14849035,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | CD80,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | INOS,2.3255814,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1,65.295172,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,3.8461540000000003,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68,0.42109484999999997,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | INOS,2.2222223,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1,30,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,1.11111115,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD80,0.30078203000000003,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,INOS,0.30078203000000003,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,PDL1,40.603860000000005,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor,36.855826,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor | PDL1,76.43979,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD20,1.4555724,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD20 | CD80,1.4925373,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD20 | INOS,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD20 | PDL1,64.179105,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD68,2.5418205,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD68 | CD80,0.34246575,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD68 | INOS,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD68 | PDL1,61.538464000000005,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,CD80,1.7379970000000002,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,INOS,0.32813781999999997,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,PDL1,13.966049,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,Tumor,19.945988,Partial Response,Y,Y,N
102-0029,030,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,On-Treatment,Tumor | PDL1,3.5360679999999998,Partial Response,Y,Y,N
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,1.1904762,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,2.1739129999999998,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,0,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,10.8589955,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,0.23419203,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.13020834,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,51.354164000000004,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,1.5004412999999999,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,0.5229613,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,0,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,0,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,22.222222,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,1.9906323,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,0.28409092,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,1.42857145,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,30.097088,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,9.674981,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,0.17976793,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,2.2248244,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,51.803140000000006,Partial Response,Y,Y,NA
102-0030,031,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.074851645,Partial Response,Y,Y,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3,1.0648596,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD3 | KI67,2.631579,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD56,0.70339977,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8,0.8599509,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,CD8 | KI67,4.3478259999999995,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,FOXP3,0.04840271,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor,8.968059,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel A,Baseline,Tumor | KI67,1.8461538,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20,0.027502750000000003,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | CD80,0,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | INOS,0,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1,50,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68,3.66732955,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | CD80,9.53373025,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | INOS,9.88095255,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1,76.07142999999999,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD68 | PDL1*INOS,8.14484135,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,CD80,1.0135931,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,INOS,34.054274,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,PDL1,18.112472500000003,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor,16.868814999999998,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel B,Baseline,Tumor | PDL1,15.100617300000001,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4,1.6480282,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1,3.5714287,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,3.3333334999999997,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | PD1*TOX,0,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TCF1/7,3.3333334999999997,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD4 | TOX,0,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163,12.033398400000001,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD68/CD163 | PD1,12.149533,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8,31.489109999999997,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1,31.214952,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.07824726,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | PD1*TOX,11.608391,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TCF1/7,0.13986015,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,CD8 | TOX,32.587412,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,PD1,34.094152,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TCF1/7,0.09510223999999999,NA,N,N,NA
102-0031,032,CD8 LOW,Nivolumab + Ipilimumab,Breast cancer,Panel C,Baseline,TOX,11.697575,NA,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3,2.3298074,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3 | KI67,0.3773585,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD56,1.38438815,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8,3.4621872000000002,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8 | KI67,1.183432,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,FOXP3,4.64423375,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor,10.743054,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor | KI67,12.6953125,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20,4.3508607999999995,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | CD80,73.27935,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | INOS,13.953489,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1,12.5,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1*INOS,1.417004,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68,3.0711958,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | CD80,67.12329,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | INOS,5.479452,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1,15.789473000000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD80,12.881656999999999,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,INOS,39.716148000000004,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,PDL1,6.491391,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor,8.328546600000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor | PDL1,23.954372,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4,16.026165,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1,9.717868000000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,3.448276,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TOX,0.7856861500000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TCF1/7,7.54717,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TOX,1.1320755,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163,10.97561,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163 | PD1,7.486631000000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8,21.686108,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1,15.056818999999999,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,2.4767801,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TOX,3.7786774000000003,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TCF1/7,37.416482,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TOX,73.68421000000001,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,PD1,13.78579,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TCF1/7,26.391379999999998,Progressive Disease,N,N,NA
102-0032,033,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TOX,22.740873999999998,Progressive Disease,N,N,NA
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,CD3,1.6868425999999999,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,CD3 | KI67,1.3818861500000001,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,CD56,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,CD8,3.84997,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,CD8 | KI67,1.2029894,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,FOXP3,0.26619344,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,Tumor,31.228351999999997,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,Baseline,Tumor | KI67,1.8910740999999998,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,CD3,10.860059,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,CD3 | KI67,10.738254999999999,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,CD56,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,CD8,19.09621,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,CD8 | KI67,42.74809,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,FOXP3,0.8746356000000001,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,Tumor,11.4431486,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel A,On-Treatment,Tumor | KI67,49.68153,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD20,7.643400250000001,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD20 | CD80,0.3144654,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD20 | INOS,0.408757905,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD20 | PDL1,10.212766,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD68,0.168028305,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD68 | CD80,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD68 | PDL1,16.228070000000002,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,CD80,0.072122541,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,INOS,0.07494284500000001,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,PDL1,9.7575125,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,Tumor,25.216755000000003,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,Baseline,Tumor | PDL1,34.736278,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD20,0.4506071,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD20 | CD80,4.5774645000000005,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD20 | INOS,63.333335,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD20 | PDL1,0.469483575,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0.35211267,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD68,1.1890323,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD68 | CD80,1.3888889,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD68 | INOS,11.5555555,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD68 | PDL1,33.2777775,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD68 | PDL1*INOS,1.6949153000000001,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,CD80,14.869594499999998,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,INOS,46.057899500000005,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,PDL1,30.403501,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,Tumor,16.089393,Progressive Disease,N,N,N
102-0033,034,CD8 LOW,Nivolumab + Ipilimumab,Hepatocellular carcinoma,Panel B,On-Treatment,Tumor | PDL1,94.225343,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3,0.41505652000000004,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3 | KI67,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD56,4.411765,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8,0.8641975,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8 | KI67,3.2128512999999996,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,FOXP3,4.556484,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor,33.56233,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor | KI67,15.993906999999998,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20,23.43265,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,43.780195,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,34.4202905,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,26.630433500000002,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,10.507246,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68,6.7876448499999995,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,50.909090000000006,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,57.045455000000004,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,52.5,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,36.1363635,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD80,31.82683,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,INOS,28.23693,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,PDL1,28.823836,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor,5.555079,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,41.666667000000004,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20,2.2815709999999996,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | CD80,17.067183,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | INOS,14.646465,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1,93.95348999999999,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,14.646465,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68,1.6199169999999998,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | CD80,12.96740225,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | INOS,9.814287,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1,50.957899999999995,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,3.8729762500000002,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD80,1.7961217500000002,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,INOS,30.764602,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,PDL1,25.2669895,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor,25.9269135,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor | PDL1,19.540522000000003,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4,7.2337575,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,0.292397665,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,17.535545,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8,0.4672897,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,0,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,37.5,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,PD1,0.1992032,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TCF1/7,1.0401188000000001,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TOX,22.572003,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4,5.177544,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1,3.90625,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.44444446,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.532567,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TCF1/7,1.9157087,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TOX,2.9496528,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163,13.247101,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163 | PD1,4.136947,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8,12.94964,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1,13.56383,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.354217655,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TOX,7.550077,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TCF1/7,3.318584,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TOX,37.254903,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,PD1,5.9764992,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,TCF1/7,0.5393072,Progressive Disease,N,N,N
102-0035,035,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,TOX,15.397350000000001,Progressive Disease,N,N,N
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3,4.4928208,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3 | KI67,1.5125983,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD56,11.5794346,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8,6.29176,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8 | KI67,15.044248,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,FOXP3,1.4063907,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor,30.344284,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor | KI67,25.057122,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20,0.824381885,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | CD80,23.0291635,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | INOS,0,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1,70.582705,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68,2.25367965,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | CD80,33.766234,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | INOS,4.5454547,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1,45.7664895,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,1.13636365,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD80,14.534718000000002,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,INOS,0.54049397,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,PDL1,26.110454,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor,26.41524,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor | PDL1,60.32937,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4,2.0020947,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1,4.3123544,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1*TOX,0,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | TCF1/7,3.8513514,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | TOX,2.4801589,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD68/CD163,7.0060982,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD68/CD163 | PD1,5.2707765,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8,26.510128,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1,3.3136095999999995,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0.18691589,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1*TOX,0.90580525,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | TCF1/7,42.646858,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | TOX,55.036300499999996,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,PD1,1.4208067,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,TCF1/7,33.931875,Partial Response,Y,Y,Y
102-0037,036,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,TOX,23.2130335,Partial Response,Y,Y,Y
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3,0.25670994999999996,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,0,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD56,0.9486977000000001,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8,0.36843181,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,3.47593595,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,FOXP3,0.14576485,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor,43.4535785,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,17.7881855,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3,3.6434613,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3 | KI67,5.4545455,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD56,3.2747775,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8,2.5590979,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8 | KI67,5.0847456,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,FOXP3,2.2613065000000003,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor,32.846403,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor | KI67,32.794735,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20,1.57531025,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,64.563492,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,3.01827155,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,5.042017,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.4201681,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68,6.304731199999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,32.92916699999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,0.5141388,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,15.023274,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.20773471000000002,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD80,10.4976747,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,INOS,1.5322254499999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,PDL1,38.1092,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor,32.7931195,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,48.1424955,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20,19.383797,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | CD80,65.038073,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | INOS,0,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1,16.676558999999997,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68,2.9937541000000003,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | CD80,5.2238807,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | INOS,0,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1,5.157593299999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD80,21.913044,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,INOS,0.096618355,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,PDL1,19.167142000000002,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor,16.196425,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor | PDL1,45.829338,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4,16.96541,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,2.8563659,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.057803467,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,0.08880995,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,0.21834061000000002,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,0.8158804,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,24.176988,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,2.0451613,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8,23.711641,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,8.681740999999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.084262375,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,5.99054155,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,15.7499195,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,65.674863,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,PD1,5.7275296000000004,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TCF1/7,14.432375999999998,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TOX,24.5990035,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4,5.2926794,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1,8.423912999999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,2.23520595,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.2140603,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TCF1/7,4.25656,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TOX,11.956522,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163,22.412573,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163 | PD1,8.523097,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8,5.093475799999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1,16.267941999999998,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,2.8138528,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TOX,7.1428575,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TCF1/7,10.2392346,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TOX,82.90043499999999,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,PD1,17.956917,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,TCF1/7,3.0058967,Stable Disease,N,N,N
102-0038,037,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,On-Treatment,TOX,16.442275000000002,Stable Disease,N,N,N
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3,0.8766503699999999,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD3 | KI67,0,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD56,3.20460535,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8,0.289986085,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,CD8 | KI67,9.090909,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,FOXP3,0.55251852,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor,19.0950795,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel A,Baseline,Tumor | KI67,10.219017000000001,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20,1.7922794,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | CD80,2.6939368999999997,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | INOS,18.309858000000002,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1,10.2564104,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD20 | PDL1*INOS,0.433029025,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68,2.5837158999999996,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | CD80,1.459854,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | INOS,9.3406595,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1,27.83505,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD68 | PDL1*INOS,2.2727273,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,CD80,0.390625,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,INOS,16.352202,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,PDL1,11.248777,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor,11.111111,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel B,Baseline,Tumor | PDL1,4.7058824,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4,15.985752999999999,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1,20.512821,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1*TCF1/7,5.7692308,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | PD1*TOX,1.6315832500000003,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | TCF1/7,11.664482,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD4 | TOX,3.9657632499999997,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD68/CD163,13.714527000000002,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD68/CD163 | PD1,12.912088999999998,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8,3.8457442,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1,27.192982999999998,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1*TCF1/7,2.9850746,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | PD1*TOX,9.552845,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | TCF1/7,21.052632,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,CD8 | TOX,17.682926,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,PD1,21.615000000000002,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,TCF1/7,12.123149,Progressive Disease,N,N,NA
102-0039,038,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma,Panel C,Baseline,TOX,12.236547999999999,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3,23.2866475,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,8.13642475,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD56,0.24055882,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8,19.2155085,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,7.737412000000001,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,FOXP3,3.85234395,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor,28.034036,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,26.5772765,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20,13.925027,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,1.4963659,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,0.042753314,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,21.6288345,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68,7.4489564999999995,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,0.7631734099999999,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,0.12437811,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,49.470173,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD80,1.7430473,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,INOS,0.05559674,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,PDL1,19.4112365,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor,27.384072000000003,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,15.374289000000001,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4,17.119285,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,5.153949,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.3333334000000001,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,3.3333334999999997,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,17.888889,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,30.277187,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,16.00902,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,3.3352837,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8,24.28705,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,4.7761194,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.36166366,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,3.0303031000000002,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,16.259712,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,38.02817,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,PD1,2.7157098,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TCF1/7,11.5776844,Progressive Disease,N,N,NA
102-0041,074,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TOX,19.609945,Progressive Disease,N,N,NA
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,32.36607,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,76.781607,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,1.1160714999999999,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,34.375,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,72.07792400000001,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,3.4226189999999996,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,31.845240000000004,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,14.719626,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,0.65645515,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,88.88889,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,88.88889,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,3.1363968,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,55.813956,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,2.3255814,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,55.813956,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,23.705325,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,39.533190000000005,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,6.1998542,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,14.733769999999998,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,1.4851485,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20,1.4188124,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | CD80,92.30769,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | INOS,59.259260000000005,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1,27.272728,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,13.074204,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68,12.685073999999998,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | CD80,13.793103,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | INOS,44.851258,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1,67.98107,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,28.375286,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD80,9.103642,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,INOS,31.756875,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,PDL1,28.293764999999997,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor,20.275863,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor | PDL1,17.278911,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4,14.10153,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1,0.57142857,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TCF1/7,0.6822612,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TOX,3.7383175,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163,17.244156999999998,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163 | PD1,14.956012499999998,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8,17.063747000000003,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1,0.5660377400000001,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TOX,0.41493779999999997,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TCF1/7,12.863071000000001,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TOX,44.90566,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,PD1,3.3805538000000004,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TCF1/7,9.948487,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TOX,14.182112,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4,16.894530999999997,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1,1.5384615000000001,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.116009275,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TOX,0.28901732999999996,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TCF1/7,0.5799434,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TOX,1.4399188,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163,22.27317,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163 | PD1,3.1212484,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8,11.907739000000001,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1,8.490566,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.85065618,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TOX,3.8596492000000002,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TCF1/7,6.534421999999999,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TOX,34.057578,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,PD1,10.801239,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TCF1/7,7.291011999999999,Progressive Disease,N,N,Y
102-0042,039,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TOX,10.340909,Progressive Disease,N,N,Y
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3,9.189957399999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,4.9535602,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD56,0.023261222999999998,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8,11.704873000000001,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,2.9850746,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,FOXP3,1.2317167,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor,29.792148,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,6.223176,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,CD3,18.246032,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,CD3 | KI67,4.7713017,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,CD56,0.020959966,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,CD8,16.384843500000002,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,CD8 | KI67,3.5077591999999997,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,FOXP3,0.6460465950000001,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,Tumor,20.9373655,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,On-Treatment,Tumor | KI67,0.5975737750000001,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20,1.5167555,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,0.69444445,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,17.8539425,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68,13.901572,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,1.25,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,0.409680315,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,29.545454,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD80,0.17376195,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,INOS,0.31272625,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,PDL1,11.176565,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor,25.557817999999997,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,17.229562,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD20,19.0535065,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD20 | CD80,1.2129976,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD20 | INOS,3.4837355500000005,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1,19.622162000000003,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0.8168821999999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD68,1.7736121999999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD68 | CD80,0.2624672,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD68 | INOS,2.0761246,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1,19.497194,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,CD80,1.8540255499999998,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,INOS,5.05717825,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,PDL1,13.905626000000002,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,Tumor,30.74257,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,On-Treatment,Tumor | PDL1,5.994207299999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4,10.9004736,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,4.0123455,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.09881423499999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,2.0289855,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,3.9772727,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,19.951923,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,29.038066,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,5.8054395,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8,12.616821999999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,1.5397669,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,0.6647128,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,2.919708,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,17.153996,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,PD1,2.3074705,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TCF1/7,1.3441955,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TOX,8.146399,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4,14.8343185,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1,1.6299288500000002,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.8478592,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TCF1/7,3.1844531500000004,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD4 | TOX,17.026669499999997,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163,31.285286,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD68/CD163 | PD1,5.204845049999999,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8,13.996281499999998,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1,0.608358,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8 | PD1*TOX,0.327977,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TCF1/7,3.0934277999999997,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,CD8 | TOX,22.012166999999998,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,PD1,2.1757274,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,TCF1/7,1.26178005,Stable Disease,N,N,NA
102-0044,075,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,On-Treatment,TOX,10.963407499999999,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,12.385431,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,9.049774,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,1.24540265,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,5.4873601,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,10.714286000000001,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.085178875,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,14.115554499999998,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,27.4735175,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,12.559952,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,84.77365999999999,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,29.714286,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,46.285716,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,13.142857,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,0.44964030000000005,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,26.666667999999998,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,26.31579,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,36.842105000000004,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,10,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,24.523160999999998,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,15.377697000000001,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,27.029973000000002,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,29.824559999999998,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,10.279001000000001,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,1.21633365,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,0,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,0,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,0,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,29.612153499999998,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,6.4128963500000005,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,45.2002895,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,15.2358405,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.37985153000000005,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,6.8235431,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,1.23888725,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,44.4768775,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,9.009910249999999,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,1.1537758999999999,Stable Disease,N,N,NA
102-0045,040,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,23.2809185,Stable Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD3,1.1400651,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD3 | KI67,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD56,0.07256894,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD8,2.3887080000000003,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD8 | KI67,2.1276595,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,FOXP3,0.8708273000000001,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,Tumor,11.509229,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,Tumor | KI67,12.941177000000001,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20,0.22050717,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | INOS,25,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | PDL1,50,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68,13.595373000000002,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | CD80,6.7976589,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | INOS,15.800562,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | PDL1,37.7357545,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | PDL1*INOS,3.89132675,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD80,2.5012290999999998,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,INOS,12.429682,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,PDL1,27.33001,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,Tumor,5.021585549999999,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,Tumor | PDL1,13.157895,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4,35.299882499999995,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1,0.26559145500000003,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | TCF1/7,1.14074617,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | TOX,0.37366061500000003,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD68/CD163,14.3201395,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD68/CD163 | PD1,0.21413276,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8,14.0832375,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1,1.1144223,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1*TOX,0.69467772,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | TCF1/7,1.1299435,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | TOX,73.62057999999999,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,PD1,0.7834411,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,TCF1/7,1.23768715,Progressive Disease,N,N,NA
102-0046,041,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,TOX,11.59311875,Progressive Disease,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD3,6.85668225,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD3 | KI67,9.8445594,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD56,0.45487521000000003,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD8,3.4720389000000003,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,CD8 | KI67,1.9230770000000001,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,FOXP3,0.272306495,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,Tumor,42.572491,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel A,Baseline,Tumor | KI67,5.93052865,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20,0.27952692,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | CD80,33.333335,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | INOS,3.57142875,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | PDL1,33.3333335,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD20 | PDL1*INOS,3.57142875,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68,13.208191500000002,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | CD80,2.61938395,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | INOS,0.761691215,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | PDL1,10.7121755,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD68 | PDL1*INOS,0.38812155000000004,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,CD80,0.86657513,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,INOS,1.0079882500000001,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,PDL1,6.22447985,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,Tumor,25.360821,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel B,Baseline,Tumor | PDL1,0.91818315,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4,30.10254,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1,0.51855088,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1*TCF1/7,0.10604454,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | PD1*TOX,0.125433565,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | TCF1/7,2.2269353,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD4 | TOX,2.4390243,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD68/CD163,27.035058,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD68/CD163 | PD1,0.7513148,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8,4.2236328,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1,4.255319,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1*TCF1/7,0,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | PD1*TOX,2.1739129999999998,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | TCF1/7,8.695651999999999,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,CD8 | TOX,36.170210000000004,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,PD1,1.7231135000000002,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,TCF1/7,2.758789,NA,N,N,NA
102-0048,042,CD8 LOW,Nivolumab + Ipilimumab,Pelvic neoplasm,Panel C,Baseline,TOX,23.191094,NA,N,N,NA
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,0.49748262499999996,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,0.64205457,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,0.10699583500000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,0.59531608,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,0.6557377,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,1.6365043999999997,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,32.78062,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,7.196247,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3,0.14134275000000002,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD3 | KI67,3.0303031000000002,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD56,7.620269,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8,0.045146726,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,CD8 | KI67,6.25,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,FOXP3,0.045146726,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor,22.618125,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,On-Treatment,Tumor | KI67,14.098361,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,1.55851635,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,12.94070165,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,8.989726000000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,38.2518465,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,2.97761325,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,0.30626993999999996,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,7.1428575,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,20.089286,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,62.23684,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,9.808612499999999,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,1.04267345,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,15.930279500000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,20.780375,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,22.8673895,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,14.6508805,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20,0.022867597,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | CD80,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | INOS,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1,50,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68,1.8877551,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | CD80,6.25,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | INOS,64.86486000000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1,45.945945,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,7.8947365000000005,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,CD80,1.7493712000000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,INOS,30.663267,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,PDL1,28.325957000000002,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor,18.939652000000002,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,On-Treatment,Tumor | PDL1,29.166666000000003,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4,0.32786885,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1,6.61938525,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,2.1276595,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TOX,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TCF1/7,2.22662045,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TOX,1.06382975,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163,1.9512758000000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163 | PD1,1.183432,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8,42.075983,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1,13.416898,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0.0449661435,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TOX,5.0906286000000005,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TCF1/7,0.066135661,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TOX,35.665914,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,PD1,28.737627999999997,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TCF1/7,0.092250924,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TOX,17.008458,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4,0.24230675999999998,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1,15.555556000000001,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TCF1/7,7.7777780000000005,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | PD1*TOX,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TCF1/7,32.647059999999996,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD4 | TOX,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163,0.7996123,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD68/CD163 | PD1,5.68181835,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8,0.11063695,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1,7.1428575,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | PD1*TOX,7.1428575,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TCF1/7,0,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,CD8 | TOX,33.333334,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,PD1,25.926821999999998,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TCF1/7,5.1752023000000005,Progressive Disease,N,N,N
103-0001,043,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,On-Treatment,TOX,4.528302,Progressive Disease,N,N,N
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,CD3,20.12343,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,CD3 | KI67,8.370895,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,CD56,0.59779407,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,CD8,11.13805,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,CD8 | KI67,10.56338,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,FOXP3,2.9291155,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,Tumor,13.852216,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,Baseline,Tumor | KI67,25.509214000000004,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,CD3,20.769269,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,CD3 | KI67,8.7603135,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,CD56,0.539791395,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,CD8,17.586574499999998,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,CD8 | KI67,9.024617,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,FOXP3,3.4980642499999997,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,Tumor,22.312006500000003,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel A,On-Treatment,Tumor | KI67,37.6963075,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD20,1.9583333,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD20 | CD80,23.809524,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD20 | INOS,7.692308000000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD20 | PDL1,39.655173,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD20 | PDL1*INOS,1.92589875,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD68,5.5124685,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD68 | CD80,70.434785,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD68 | INOS,8.260869,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD68 | PDL1,86.14232,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD68 | PDL1*INOS,5.1282052,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,CD80,27.9043,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,INOS,29.984543000000002,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,PDL1,26.010746,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,Tumor,24.791667,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,Baseline,Tumor | PDL1,14.427570000000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD20,5.2826185,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD20 | CD80,19.253939000000003,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD20 | INOS,9.3327968,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD20 | PDL1,26.308718499999998,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,1.7949189999999997,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD68,6.940561000000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD68 | CD80,41.952516,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD68 | INOS,16.6125175,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD68 | PDL1,90.040792,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,11.9298575,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,CD80,21.773422500000002,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,INOS,27.703065000000002,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,PDL1,30.164697,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,Tumor,22.2619585,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel B,On-Treatment,Tumor | PDL1,10.780545,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4,13.054617,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4 | PD1,23.166887,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,3.39208075,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4 | PD1*TOX,1.03508585,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4 | TCF1/7,4.707417749999999,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD4 | TOX,2.09530515,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD68/CD163,10.733187999999998,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD68/CD163 | PD1,14.9148245,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8,11.0525895,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8 | PD1,13.985295,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,1.1048845250000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8 | PD1*TOX,4.5931686,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8 | TCF1/7,26.251339,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,CD8 | TOX,42.9268025,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,PD1,30.08868,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,TCF1/7,6.64868815,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,Baseline,TOX,28.1268875,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4,13.917610499999999,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4 | PD1,30.702361500000002,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,5.3343287,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.7657028000000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4 | TCF1/7,14.1889635,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD4 | TOX,4.088802449999999,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD68/CD163,9.685856000000001,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD68/CD163 | PD1,23.0113215,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8,13.308696,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8 | PD1,41.3223845,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,9.49482395,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8 | PD1*TOX,9.626341799999999,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8 | TCF1/7,35.043341999999996,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,CD8 | TOX,24.523039,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,PD1,40.8996015,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,TCF1/7,14.6209545,Partial Response,Y,Y,NA
103-0003,076,CD8 HIGH,Nivolumab,Gastrooesophageal cancer,Panel C,On-Treatment,TOX,15.8627215,Partial Response,Y,Y,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,6.0356609500000005,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,3.4453451499999996,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,17.368552,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,2.59539115,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,2.969906,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.8627103,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,30.618748,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,13.630297000000002,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,0.5509642,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,3.647215,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,24.13793,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,17.24138,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,6.896552,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,12.733490999999999,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,2.2653721,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,22.520661,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,8.057851000000001,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,2.0661157,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,34.896153000000005,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,23.771335,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,2.9992107,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,38.330248,NA,N,N,NA
104-0001,044,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.3218884,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3,2.9759431999999997,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,7.9200595499999995,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD56,2.17274545,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8,1.212519025,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,13.192982749999999,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,FOXP3,1.8903778,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor,35.680288000000004,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,12.9195257,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20,10.8367346,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,1.3182675,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,0,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,6.591337,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68,5.8047492,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,10.843374,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,0.9740259500000001,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,57.14286,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD80,3.7959184,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,INOS,0.3877551,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,PDL1,28.142857999999997,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor,19.298907,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,27.224007,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4,8.747382,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,2.4390243,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.25,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,1.21951215,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,0.25,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,2.6890243,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,17.5005515,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,2.2820513,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8,20.901622500000002,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,4.38852385,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.064350065,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,4.25965785,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,1.4157014,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,61.0465485,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,PD1,3.6614239500000005,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TCF1/7,0.32446295999999997,NA,N,N,NA
104-0002,045,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TOX,15.703268,NA,N,N,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD3,15.012106,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD3 | KI67,3.763441,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD56,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD8,4.439063699999999,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD8 | KI67,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,FOXP3,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,Tumor,23.648103000000003,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,Tumor | KI67,2.7303753,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20,1.168858235,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | CD80,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | INOS,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | PDL1,11.904762250000001,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68,8.3734345,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | INOS,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | PDL1,31.524045,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD80,0.06983239999999999,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,INOS,0,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,PDL1,27.5724935,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,Tumor,18.656423,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,Tumor | PDL1,83.16156000000001,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4,4.2276304499999995,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1,5.514705999999999,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,2.9411765,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TOX,2.9411765,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | TCF1/7,22.794118000000005,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | TOX,23.161765000000003,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD68/CD163,31.1058725,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD68/CD163 | PD1,0.43041609999999997,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8,5.274782350000001,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1,4.725877199999999,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.5263158,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TOX,2.10526325,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | TCF1/7,10.504386400000001,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | TOX,48.5307035,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,PD1,0.6636219000000001,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,TCF1/7,5.33904985,Partial Response,Y,Y,NA
104-0005,046,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,TOX,14.05215025,Partial Response,Y,Y,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3,2.4952015000000003,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3 | KI67,1.9108279999999997,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD56,2.0260183,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8,1.5023475,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8 | KI67,2.631579,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,FOXP3,0.70564514,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor,35.062927,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor | KI67,15.439430000000002,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20,0.52882074,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | CD80,61.904765,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | INOS,9.761905,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1,30.769232000000002,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1*INOS,4.5454547,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68,6.0539752,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | CD80,45.384616,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | INOS,3.4926220999999993,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1,12.048193,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1*INOS,1,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD80,11.5665354,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,INOS,15.160023,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,PDL1,5.9872612,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor,29.20411,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor | PDL1,1.0638298,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4,8.529627999999999,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1,6.690654,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.6066734,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TOX,1.3613518,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TCF1/7,2.03450257,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TOX,4.6348315,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163,11.932205749999998,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163 | PD1,1.9260317,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8,6.7937525,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1,9.716671999999999,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.0240615975,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TOX,4.964423200000001,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TCF1/7,5.559471500000001,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TOX,50.565838,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,PD1,18.236746500000002,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TCF1/7,5.1166545,Progressive Disease,N,N,NA
104-0006,047,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TOX,13.1458893,Progressive Disease,N,N,NA
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3,10.553337,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3 | KI67,1.6216217000000002,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD56,1.3690815,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8,3.6508843,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8 | KI67,3.125,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,FOXP3,1.654307,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor,23.388476999999998,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor | KI67,0.24390244,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD3,7.821229000000001,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD3 | KI67,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD56,0.46296295000000004,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD8,5.7985757,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD8 | KI67,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,FOXP3,0.10746675350000001,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,Tumor,37.037036,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,Tumor | KI67,0.775862085,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20,0.164366325,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1,50,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68,2.2047895,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | CD80,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | INOS,21.703297499999998,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1,66.20879199999999,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1*INOS,21.703297499999998,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD80,5.1924816,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,INOS,7.82273635,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,PDL1,18.364987499999998,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor,39.068066,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor | PDL1,5.52953515,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20,5.2063964,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | CD80,0.35714285,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | PDL1,0.7142857,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68,0.5578282,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | CD80,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | PDL1,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD80,0.11074197,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,INOS,0.11074197,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,PDL1,0.3322259,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,Tumor,19.980602,Stable Disease,N,N,N
104-0007,048,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,Tumor | PDL1,0,Stable Disease,N,N,N
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,CD3,29.7069385,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,CD3 | KI67,3.7233881999999996,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,CD56,1.46147425,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,CD8,16.2989935,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,CD8 | KI67,0.9310273,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,FOXP3,3.9010107000000005,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,Tumor,12.385779200000002,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,Baseline,Tumor | KI67,30.833334,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,CD3,20.198338,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,CD3 | KI67,2.5992779,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,CD56,0.029167274,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,CD8,13.037771000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,CD8 | KI67,2.6845638000000003,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,FOXP3,1.37086185,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,Tumor,29.006853999999997,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel A,On-Treatment,Tumor | KI67,24.534942,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD20,6.067961,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD20 | CD80,0.8888889000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD20 | INOS,7.199999999999999,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD20 | PDL1,27.555555,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.23923445,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD68,6.4131245,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD68 | CD80,1.1627907,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD68 | INOS,32.608697,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD68 | PDL1,19.005848,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD68 | PDL1*INOS,3.6231883,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,CD80,7.713053,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,INOS,29.017553000000003,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,PDL1,19.537658999999998,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,Tumor,12.602535000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,Baseline,Tumor | PDL1,93.19371600000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD20,5.8334825,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD20 | CD80,16.117216499999998,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD20 | INOS,37.8499665,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD20 | PDL1,44.778614000000005,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,14.874793500000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD68,16.4857815,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD68 | CD80,12.7764022,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD68 | INOS,50.025675,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD68 | PDL1,35.3126565,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,12.303968999999999,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,CD80,34.6332045,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,INOS,33.7345825,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,PDL1,19.8200815,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,Tumor,26.327955,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel B,On-Treatment,Tumor | PDL1,12.0190485,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4,11.611571000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4 | PD1,2.754155,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.37383179,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4 | PD1*TOX,1.2581310499999998,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4 | TCF1/7,8.48643525,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD4 | TOX,16.887833999999998,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD68/CD163,23.5809335,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD68/CD163 | PD1,10.7178045,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8,11.3655808,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8 | PD1,0.43836445,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8 | PD1*TOX,0.286808985,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8 | TCF1/7,7.05477055,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,CD8 | TOX,15.492081,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,PD1,3.6275935000000006,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,TCF1/7,3.0212728500000003,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,Baseline,TOX,21.6661055,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4,14.518355,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4 | PD1,25.475284,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,2.1863118,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4 | PD1*TOX,4.4676807,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4 | TCF1/7,12.452471,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD4 | TOX,16.159695,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD68/CD163,25.37952,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD68/CD163 | PD1,37.95541,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8,6.2241238,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8 | PD1,7.317073000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.44345898000000006,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8 | PD1*TOX,1.330377,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8 | TCF1/7,7.760532,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,CD8 | TOX,14.855877000000001,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,PD1,13.483301,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,TCF1/7,3.1741650000000003,Progressive Disease,N,N,NA
104-0008,077,CD8 HIGH,Nivolumab,Urethral cancer,Panel C,On-Treatment,TOX,20.107646000000003,Progressive Disease,N,N,NA
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,CD3,13.493464999999999,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,CD3 | KI67,0.655308,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,CD56,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,CD8,12.325711,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,CD8 | KI67,0.9049774,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,FOXP3,0.17661604,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,Tumor,21.58248,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,Baseline,Tumor | KI67,18.998979,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,CD3,8.172674,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,CD3 | KI67,6.6666669999999995,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,CD56,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,CD8,5.658005,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,CD8 | KI67,1.4814815000000001,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,FOXP3,0.29337804,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,Tumor,31.559095,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel A,On-Treatment,Tumor | KI67,35.856575,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD20,9.933436,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD20 | CD80,0.5291005,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD20 | INOS,4.232804,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD20 | PDL1,1.0309278,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD68,3.0209934,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD68 | CD80,2.1008404,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD68 | INOS,17.64706,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD68 | PDL1,4.411765,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD68 | PDL1*INOS,1.6949152499999998,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,CD80,0.7815892,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,INOS,2.9960921000000003,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,PDL1,17.153098,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,Tumor,29.353016999999998,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,Baseline,Tumor | PDL1,44.822484,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD20,0.30975735,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD20 | CD80,50,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD20 | INOS,16.666667,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD20 | PDL1,16.666667,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD68,2.942695,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD68 | CD80,12.280702,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD68 | INOS,73.68421000000001,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD68 | PDL1,59.649119999999996,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,38.59649,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,CD80,21.631387999999998,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,INOS,32.059886999999996,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,PDL1,28.807433999999997,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,Tumor,26.12287,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel B,On-Treatment,Tumor | PDL1,64.426875,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4,10.065076000000001,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4 | PD1,29.654035,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,7.907743,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4 | PD1*TOX,11.861614,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4 | TCF1/7,27.155172999999998,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD4 | TOX,29.951692,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD68/CD163,15.422611999999999,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD68/CD163 | PD1,25.319692,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8,5.7903400000000005,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8 | PD1,7.582939,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.729927,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8 | PD1*TOX,3.409091,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8 | TCF1/7,21.167883,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,CD8 | TOX,27.272728,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,PD1,13.752711000000001,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,TCF1/7,20.347072,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,Baseline,TOX,19.088937,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4,5.185185,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4 | PD1,5.7142857,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.1428571,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4 | TCF1/7,26.857143999999998,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD4 | TOX,9.142857,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD68/CD163,8.533333,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD68/CD163 | PD1,24.305555000000002,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8,9.155555999999999,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8 | PD1,9.3851134,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8 | PD1*TOX,3.883495,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8 | TCF1/7,5.501618199999999,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,CD8 | TOX,19.093852,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,PD1,3.3777777,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,TCF1/7,10.459259,Stable Disease,N,N,N
104-0009,049,CD8 LOW,Nivolumab + Ipilimumab,Penile cancer,Panel C,On-Treatment,TOX,6.42963,Stable Disease,N,N,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD3,17.008547,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD3 | KI67,1.6,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD56,0.16611295,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD8,12.735043,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,CD8 | KI67,0.33557047,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,FOXP3,33.193278,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,Tumor,16.324787,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,Baseline,Tumor | KI67,5.4545455,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,CD3,19.220280000000002,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,CD3 | KI67,1.00148813,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,CD56,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,CD8,3.6673287,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,CD8 | KI67,1.5199213,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,FOXP3,0.22495758,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,Tumor,36.654408000000004,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel A,On-Treatment,Tumor | KI67,1.4179059,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20,20.441989999999997,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | CD80,0.45045045999999994,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | INOS,40.54054,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | PDL1,2.7027028,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.45045045999999994,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68,3.038674,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | CD80,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | INOS,33.333334,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | PDL1,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,CD80,0.2762431,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,INOS,28.54512,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,PDL1,14.917127999999998,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,Tumor,15.285452,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,Baseline,Tumor | PDL1,92.771083,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD20,12.398508499999998,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD20 | CD80,3.17160575,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD20 | INOS,53.272123,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD20 | PDL1,2.21331595,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD68,1.9860724,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD68 | CD80,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD68 | INOS,2.25497605,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD68 | PDL1,9.04509915,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,CD80,0.5665235,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,INOS,17.571579,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,PDL1,25.282905500000002,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,Tumor,40.6473265,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel B,On-Treatment,Tumor | PDL1,56.984612,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4,6.0103085,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | TCF1/7,4.319275,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD4 | TOX,31.6870155,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD68/CD163,22.810944999999997,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD68/CD163 | PD1,9.696606800000001,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8,7.9966952000000004,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1,3.0913684,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TOX,1.9108279999999997,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | TCF1/7,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,CD8 | TOX,28.1023505,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,PD1,2.2552972,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,TCF1/7,0.688669585,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,Baseline,TOX,36.477156,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4,3.977944,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1,7.1428575,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1*TOX,2.970297,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4 | TCF1/7,4.950495,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD4 | TOX,9.90099,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD68/CD163,24.202335,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD68/CD163 | PD1,10.096153600000001,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8,6.971247999999999,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1,1.2658228,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1*TOX,1.2658228,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8 | TCF1/7,2.5316456,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,CD8 | TOX,45.754716,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,PD1,10.700389000000001,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,TCF1/7,0.7877116999999999,Partial Response,Y,Y,N
104-0010,050,CD8 LOW,Nivolumab + Ipilimumab,Renal cancer,Panel C,On-Treatment,TOX,14.435798,Partial Response,Y,Y,N
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,CD3,8.736217,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,CD3 | KI67,0.6472492,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,CD56,0.07027407,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,CD8,8.889669999999999,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,CD8 | KI67,0.8032128,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,FOXP3,4.7083627,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,Tumor,25.162565999999998,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel A,Baseline,Tumor | KI67,65.39326,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD20,1.4518792,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD20 | CD80,0,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD20 | INOS,2.3255814,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD20 | PDL1,8.695651999999999,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD68,3.5823255000000005,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD68 | CD80,12.5,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD68 | INOS,4.1428572,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD68 | PDL1,3.125,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,CD80,1.02102495,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,INOS,4.19321135,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,PDL1,0.49049303,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,Tumor,16.153706,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel B,Baseline,Tumor | PDL1,0.8,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4,15.405994,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4 | PD1,11.255130999999999,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4 | PD1*TCF1/7,4.390834999999999,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4 | PD1*TOX,0.43862759,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4 | TCF1/7,9.2674595,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD4 | TOX,1.6758388499999999,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD68/CD163,4.96044485,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD68/CD163 | PD1,2.5993712,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8,2.6852739999999997,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8 | PD1,2.0204081499999997,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8 | PD1*TOX,1.81818175,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8 | TCF1/7,7.1428571000000005,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,CD8 | TOX,7.75510205,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,PD1,8.7678068,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,TCF1/7,20.954819999999998,Progressive Disease,N,N,NA
104-0014,051,CD8 LOW,Nivolumab + Ipilimumab,Tumour of ampulla of Vater,Panel C,Baseline,TOX,2.0021164,Progressive Disease,N,N,NA
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3,8.075629,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD3 | KI67,0.8421052,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD56,0,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8,0.839223725,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,CD8 | KI67,2.3809525000000002,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,FOXP3,0.10072361,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor,35.784881,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,Baseline,Tumor | KI67,1.253343125,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD3,19.180664,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD3 | KI67,12.2262776,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD56,0.0172532775,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD8,7.688012,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,CD8 | KI67,15.980630000000001,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,FOXP3,1.7099863,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,Tumor,27.624720000000003,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel A,On-Treatment,Tumor | KI67,6.334231999999999,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20,4.733921,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | CD80,7.1428575,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | INOS,1.1904762,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1,8.799999999999999,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.1572327,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68,0.4108074,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | CD80,13.724105999999999,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | INOS,2.7777778,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1,11.764706,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD68 | PDL1*INOS,2.4390243,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,CD80,3.4286619999999997,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,INOS,0.8992806000000001,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,PDL1,12.2409075,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor,31.750974,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,Baseline,Tumor | PDL1,36.016598,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20,2.5065962,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | CD80,14.285715,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | INOS,22.522523,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | PDL1,58.620689999999996,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,2.5210084,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68,6.7281105,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | CD80,9.45946,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | INOS,33.093524,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | PDL1,55.419225000000004,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,8.558559,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,CD80,16.09138,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,INOS,23.595928999999998,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,PDL1,20.221046,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,Tumor,28.119670000000003,Stable Disease,N,N,N
104-0015,052,CD8 LOW,Nivolumab + Ipilimumab,Thyroid cancer,Panel B,On-Treatment,Tumor | PDL1,7.9027354999999995,Stable Disease,N,N,N
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD3,3.264762,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD3 | KI67,0.971039835,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD56,1.63586515,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD8,1.31297065,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,CD8 | KI67,3.0100335,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,FOXP3,6.09830285,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,Tumor,28.331892000000003,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel A,Baseline,Tumor | KI67,14.012994500000001,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20,11.091243500000001,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | CD80,86.84294750000001,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | INOS,24.547697499999998,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1,14.285321,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD20 | PDL1*INOS,3.28002035,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68,1.0058882,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | CD80,80.3571435,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | INOS,41.94182300000001,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1,3.4848485,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD68 | PDL1*INOS,5.83333355,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,CD80,26.731826500000004,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,INOS,22.8791355,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,PDL1,6.3527783,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor,25.228584,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel B,Baseline,Tumor | PDL1,0.8747393,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4,4.344312,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1,7.1428575,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.7936508,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | PD1*TOX,0,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TCF1/7,3.1746034,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD4 | TOX,0.255102035,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163,8.5875936,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD68/CD163 | PD1,8.504399,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8,12.674709,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1,13.07786,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.4531722,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | PD1*TOX,5.042017,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TCF1/7,4.6827793,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,CD8 | TOX,61.027193000000004,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,PD1,25.942945,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TCF1/7,1.359372,NA,N,N,NA
104-0016,053,CD8 LOW,Nivolumab + Ipilimumab,Uterine cancer,Panel C,Baseline,TOX,20.639478999999998,NA,N,N,NA
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,13.507209800000002,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,1.02040815,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,0.040420372,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,7.9745854000000005,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.17814394,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,21.089364,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,0.910417485,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3,19.4331225,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3 | KI67,4.5354035,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD56,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8,14.3361573,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8 | KI67,2.6953146,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,FOXP3,0.8843188850000001,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor,35.282533,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor | KI67,5.54273685,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,1.7482517,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,5,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,20,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,4.5454547,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,3.8461540000000003,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,4.7619050000000005,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,15.384616000000001,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,2.5,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,2.9761905,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,4.404762,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,20.821919,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,1.4492754,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20,3.6649216,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | CD80,2.8571429,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | INOS,17.142858,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1,47.923324,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,2.8571429,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68,4.584413,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | CD80,3.0434782,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | INOS,15.652173999999999,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1,9.565216999999999,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0.4347826,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD80,17.801672,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,INOS,22.34403,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,PDL1,6.896552,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor,41.45904,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor | PDL1,0.096153846,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,15.110787,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,0.3267974,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,0.3267974,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,4.9730037,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,12.5461785,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,19.6244095,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,1.40114895,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,9.07331725,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,4.5444665,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,18.1778655,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,0.3983382,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,2.044872925,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,17.393838,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4,10.402295,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1,2.35175655,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.4576659,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TOX,1.9512194999999999,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TCF1/7,4.30297605,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TOX,14.0031,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163,21.718384999999998,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163 | PD1,1.14569965,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8,8.5409345,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1,3.06991505,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TOX,2.1924791,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TCF1/7,2.0737143,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TOX,32.8676315,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,PD1,0.75389885,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TCF1/7,0.77717937,Stable Disease,N,Y,N
104-0018,054,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TOX,18.36108,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,10.6944192,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,3.3836768999999998,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,14.211034999999999,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,0.52160955,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0.02735978,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,22.333720999999997,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,6.9620495,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3,5.4896579,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3 | KI67,0.53030302,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD56,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8,11.6484265,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8 | KI67,0.10548522500000002,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,FOXP3,0.029868577500000004,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor,41.45335,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor | KI67,1.3637229499999999,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,0.024277737,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,6.4812385,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,5.5555556,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,28.282826999999997,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,18.434343000000002,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,2.5252525,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,19.968512999999998,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,29.925847,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,4.528602,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,32.20339,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.16853933,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20,3.0732227500000002,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | CD80,0,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | INOS,8.4434086,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1,1.84937615,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0.14245014,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68,5.89056585,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | CD80,0.21978023000000002,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | INOS,5.01231535,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1,10.2083332,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0.97697755,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD80,8.4811652,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,INOS,7.63821525,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,PDL1,2.29669905,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor,40.910743499999995,Stable Disease,N,Y,N
104-0020,055,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor | PDL1,0.2314534125,Stable Disease,N,Y,N
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,14.080882,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,4.4386424,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,2.4264706,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,14.264705999999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,7.2164945,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,21.102941,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,16.72794,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,2.1978022999999998,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,0.16458969999999998,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,15,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,10,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,31.666667,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,12.602869,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,21.631205,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,5.6277055,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,39.434725,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.9762900999999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,34.927085000000005,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,23.650794,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,6.515359,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,37.48719,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.36540804,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,17.7137415,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,2.72444925,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.10672358,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,0.96785242,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,10.914586750000002,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,15.928106249999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,42.2985895,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,1.5905086499999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,7.0550289,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,9.96859915,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,5.729468499999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,2.37922705,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,20.0564385,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,1.9560629,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,2.2665524,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,14.0703846,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4,13.147003250000001,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1,1.00463425,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.29771398,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TCF1/7,3.3501718499999997,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TOX,12.471527499999999,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163,40.4803305,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163 | PD1,1.46112667,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8,10.933796,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1,2.99681935,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TOX,1.127805795,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TCF1/7,0.4978743,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TOX,33.6759105,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,PD1,1.83531615,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TCF1/7,0.831507785,Partial Response,Y,Y,Y
104-0021,056,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TOX,27.1682695,Partial Response,Y,Y,Y
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3,23.8871995,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,3.04634845,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD56,0.841689135,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8,17.2800935,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,0.13966479999999998,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,FOXP3,0.07846214,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor,23.655972,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,7.440241100000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3,33.509865000000005,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3 | KI67,0.46731106,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD56,3.3501705,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8,11.197282000000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8 | KI67,0.5076142,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,FOXP3,0.08232711000000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor,33.727322,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor | KI67,4.490202200000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20,1.3396375,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,14.766081499999999,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,19.785575,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,7.8947365000000005,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,7.797271,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68,9.2986606,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,0,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,0.363636365,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,11.440678,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.363636365,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD80,1.2569833000000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,INOS,1.2290503,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,PDL1,26.863619999999997,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor,23.600137,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,67.84314,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20,1.7992651999999998,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | CD80,12.6811595,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | INOS,9.109731,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1,13.263311999999999,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,5.263158,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68,5.8713792,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | CD80,1.4928699,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | INOS,2.49554375,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1,8.666297,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0.9803921999999999,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD80,8.1867055,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,INOS,3.4564174000000003,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,PDL1,31.895825000000002,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor,41.828379999999996,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor | PDL1,67.11859799999999,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4,5.07685185,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,2.277328,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,0.60099575,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,10.662139,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,19.151103499999998,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,33.5372785,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,11.6410205,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8,5.1198916,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,0.55555555,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,0.277777785,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,1.6853931999999998,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,9.48814,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,PD1,4.38649225,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TCF1/7,2.26553845,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TOX,18.465836,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4,2.7991887,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1,4.5454547,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TOX,3.55477865,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TCF1/7,1.3343937750000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TOX,21.95122,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163,31.186095,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163 | PD1,7.217847600000001,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8,2.5963488999999997,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1,1.6666668,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TOX,3.1862747,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TCF1/7,0.93002955,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TOX,46.153846,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,PD1,3.245436,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TCF1/7,3.9367430000000003,Progressive Disease,N,N,N
104-0022,057,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TOX,23.412699,Progressive Disease,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3,0.070047225,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3 | KI67,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD56,10.700608,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8,0.034904014,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8 | KI67,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,FOXP3,0.054708592,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor,24.816267,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor | KI67,11.135612,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD3,0.13577731999999998,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD3 | KI67,3.1887496,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD56,10.252578,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD8,0.050632909999999996,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD8 | KI67,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,FOXP3,0.0312774435,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,Tumor,18.787618000000002,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,Tumor | KI67,15.860427999999999,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20,0.36656890999999997,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | CD80,88.88889,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | INOS,8.125,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1,17.8125,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68,5.402398499999999,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | CD80,60.792950000000005,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | INOS,25,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1,33.333334,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1*INOS,5.034325,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD80,25.680694,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,INOS,21.920821,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,PDL1,11.5384616,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor,33.211144999999995,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor | PDL1,24.466571000000002,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20,1.4867970700000002,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | CD80,1.3961606,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | INOS,0.7352941,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | PDL1,74.63235,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68,4.46548885,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | CD80,13.1912445,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | INOS,0.35842294,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | PDL1,42.2491045,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0.0448028675,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD80,1.6864589,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,INOS,0.16857034999999998,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,PDL1,31.5274285,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,Tumor,27.805087,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,Tumor | PDL1,47.0863175,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4,3.3089695,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1,3.20320325,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.0416667,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TOX,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TCF1/7,1.17508815,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TOX,1.8518519,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163,2.7733016,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163 | PD1,4.6703297500000005,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8,1.394178325,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1,7.407407500000001,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TOX,4,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TCF1/7,5.000000099999999,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TOX,9.814815,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,PD1,12.5773052,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TCF1/7,0.49025960999999996,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TOX,52.298516,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4,3.1602613999999996,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1,7.605634,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.7528634825,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.13003901,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | TCF1/7,1.3656413,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | TOX,0.26548105,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD68/CD163,5.1367728,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD68/CD163 | PD1,4.36988345,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8,12.035253999999998,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1,12.0139412,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.08605852,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1*TOX,3.71521285,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | TCF1/7,0.8348921499999999,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | TOX,23.409004500000002,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,PD1,14.793292000000001,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,TCF1/7,0.16232288,NA,N,N,N
104-0023,058,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,TOX,23.944541,NA,N,N,N
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,CD3,25.069038499999998,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,CD3 | KI67,1.029882975,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,CD56,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,CD8,23.864365999999997,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,CD8 | KI67,0.39472557999999996,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,FOXP3,0.0969675,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,Tumor,15.0485215,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,Baseline,Tumor | KI67,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,CD3,25.76041,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,CD3 | KI67,1.1213720999999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,CD56,0.11894646999999998,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,CD8,14.018692,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,CD8 | KI67,2.5454545,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,FOXP3,1.3423958999999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,Tumor,22.786745,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel A,On-Treatment,Tumor | KI67,0.52199853,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD20,0.6830691280000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD20 | CD80,3.92156875,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD20 | INOS,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD20 | PDL1,50,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD68,10.4392876,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD68 | CD80,0.7621951499999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD68 | PDL1,17.4231505,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,CD80,0.155642895,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,INOS,0.032226878,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,PDL1,22.0231475,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,Tumor,13.403940500000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,Baseline,Tumor | PDL1,79.9964035,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD20,11.09317,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD20 | CD80,6.256151399999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD20 | INOS,15.954574000000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD20 | PDL1,49.34658399999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,4.0553105,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD68,9.2882673,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD68 | CD80,0.2504028,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD68 | INOS,3.60724335,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD68 | PDL1,16.990266499999997,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0.77751125,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,CD80,2.6396654,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,INOS,10.033824000000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,PDL1,15.738112000000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,Tumor,15.7757605,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel B,On-Treatment,Tumor | PDL1,8.810569000000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4,9.3878535,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4 | PD1,0.6887052,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4 | PD1*TOX,0.5509642,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4 | TCF1/7,2.411751625,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD4 | TOX,35.786151000000004,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD68/CD163,40.75043049999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD68/CD163 | PD1,0.39321166,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8,10.5297337,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8 | PD1,5.0008965,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8 | PD1*TOX,2.3307626999999997,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8 | TCF1/7,5.70378135,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,CD8 | TOX,18.243271,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,PD1,0.793350075,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,TCF1/7,0.90414302,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,Baseline,TOX,28.508138,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4,10.916692999999999,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1,12.608695,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,0.42553189999999996,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4 | PD1*TOX,6.521739,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4 | TCF1/7,21.832883,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD4 | TOX,26.808510000000002,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD68/CD163,29.544749999999997,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD68/CD163 | PD1,2.375,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8,15.685971000000002,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1,1.6666668,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0.047709925,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8 | PD1*TOX,0.8884502000000001,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8 | TCF1/7,8.785785,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,CD8 | TOX,17.374136,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,PD1,3.468566,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,TCF1/7,5.4660887,Progressive Disease,N,N,NA
104-0024,078,CD8 HIGH,Nivolumab,Renal cancer,Panel C,On-Treatment,TOX,17.420255,Progressive Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,0.48459675,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,16.095534999999998,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,0.72689513,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,5.9882313,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,6.3583810000000005,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,2.3537803,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,3.0303031000000002,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,57.575756,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,3.9942940000000005,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,48.214287,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,10.714286000000001,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,41.07143,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,1.7857143999999998,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,17.83167,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,14.265335,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,20.542082,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,11.412268000000001,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,16.875,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,7.0402965,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,8.552632000000001,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,0,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,9.263548,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,2,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,17.508106,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,20.634921000000002,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,1.3227513,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,18.253969,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,7.1428575,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,65.07937,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,10.328856,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,4.446503,Stable Disease,N,N,NA
104-0025,059,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,15.284854000000001,Stable Disease,N,N,NA
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3,10.2916217,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD3 | KI67,0.6801424,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD56,3.45356355,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8,4.4912148,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,CD8 | KI67,1.5021930000000001,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,FOXP3,2.112491115,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor,26.5001925,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,Baseline,Tumor | KI67,3.30377515,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3,1.21951215,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD3 | KI67,8.3333336,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD56,0.09587728000000001,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8,0.9872242,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,CD8 | KI67,0.4672897,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,FOXP3,15.615986000000001,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor,29.15215,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel A,On-Treatment,Tumor | KI67,6.2857140000000005,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20,3.4611814,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | INOS,2.739726,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68,3.85331975,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | CD80,0.8,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | INOS,10.4,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,CD80,0.9078222499999999,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,INOS,5.505945,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,PDL1,0.585901715,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor,10.9058985,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,Baseline,Tumor | PDL1,0.14124293999999998,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20,0.535193305,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | CD80,22.5,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1,70.833335,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68,6.5391575,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | CD80,3.7466131000000003,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1,71.7607965,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,CD80,0.607509375,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,INOS,0.0207900215,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,PDL1,24.8336125,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor,26.460067,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel B,On-Treatment,Tumor | PDL1,4.3944703999999994,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4,10.27858325,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1,8.722826,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,2.46376815,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | PD1*TOX,0.35842295,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TCF1/7,13.9516125,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD4 | TOX,1.0869564999999999,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163,16.553079999999998,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD68/CD163 | PD1,7.5299382,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8,24.732594,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1,36.320166,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,1.4553014,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | PD1*TOX,24.37706,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TCF1/7,2.7234927000000004,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,CD8 | TOX,69.529435,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,PD1,26.461743,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TCF1/7,6.3442479999999994,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,Baseline,TOX,21.696353000000002,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4,3.4600113,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1,5,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.0989011499999999,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | PD1*TOX,3.5989011499999997,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TCF1/7,2.19780225,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD4 | TOX,6.593407,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163,10.425239999999999,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD68/CD163 | PD1,1.3157895,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8,12.537313999999999,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1,7.1428575,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | PD1*TOX,5.263158,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TCF1/7,0.7168459,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,CD8 | TOX,56.38095,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,PD1,23.312536,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TCF1/7,0.15960215,Stable Disease,N,N,N
104-0026,060,CD8 LOW,Nivolumab + Ipilimumab,Prostate cancer,Panel C,On-Treatment,TOX,20.164609,Stable Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,CD3,7.768053,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,CD3 | KI67,0,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,CD56,7.3304154,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,CD8,0.65645515,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,CD8 | KI67,16.666667,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,FOXP3,0.9846827,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,Tumor,32.166302,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,Baseline,Tumor | KI67,0.34013605,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,CD3,26.067615,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,CD3 | KI67,13.993174,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,CD56,1.9572954999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,CD8,3.8256228000000005,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,CD8 | KI67,0,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,FOXP3,2.4911031,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,Tumor,27.758008,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel A,On-Treatment,Tumor | KI67,0.64102565,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20,7.3567149999999994,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | CD80,67.44185999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | INOS,41.860464,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | PDL1,10.465116,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,9.3023255,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68,2.7373824,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | CD80,18.75,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | INOS,21.875,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | PDL1,9.375,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,9.375,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,CD80,11.035072999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,INOS,13.430281999999998,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,PDL1,3.507271,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,Tumor,38.665527,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,Baseline,Tumor | PDL1,3.0973451,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD20,18.118629,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD20 | CD80,1.0230179000000001,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD20 | INOS,17.902814,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD20 | PDL1,59.33503999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD20 | PDL1*INOS,7.1611255,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD68,1.7608898000000002,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD68 | CD80,2.631579,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD68 | INOS,18.421052,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD68 | PDL1,34.210527,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD68 | PDL1*INOS,5.263158,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,CD80,19.694160999999998,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,INOS,20.111214,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,PDL1,18.721038,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,Tumor,26.69138,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel B,On-Treatment,Tumor | PDL1,1.5625,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4,28.57143,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4 | PD1,1.5384615000000001,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0.5747126499999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4 | PD1*TOX,1.1494252999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4 | TCF1/7,4.2682927,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD4 | TOX,6.443298599999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD68/CD163,19.786096,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD68/CD163 | PD1,0.8264462,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8,4.6263345,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8 | PD1,6.6666669999999995,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8 | PD1*TOX,1.0869564999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8 | TCF1/7,7.1428575,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,CD8 | TOX,29.670331,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,PD1,0.9174311500000001,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,TCF1/7,2.6570047999999997,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,Baseline,TOX,13.523131999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4,28.887770000000003,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4 | PD1,5.4006968,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.0373444,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4 | PD1*TOX,0.41493779999999997,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4 | TCF1/7,9.2334494,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD4 | TOX,3.1358887,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD68/CD163,21.067515,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD68/CD163 | PD1,2.117647,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8,14.609285999999999,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8 | PD1,7.234043,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8 | PD1*TCF1/7,1.1627907,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8 | PD1*TOX,3.2407407,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8 | TCF1/7,9.7222224,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,CD8 | TOX,48.062015,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,PD1,6.342016,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,TCF1/7,9.9093996,Progressive Disease,N,N,N
106-0001,061,CD8 LOW,Nivolumab + Ipilimumab,Peritoneal sarcoma,Panel C,On-Treatment,TOX,11.9830325,Progressive Disease,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3,0.414931775,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,50,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD56,1.1160624,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8,0.4772796,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,20,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,FOXP3,0.61207735,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor,35.4379595,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,13.03125,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3,1.3753,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD3 | KI67,1.3422819000000001,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD56,5.108486999999999,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8,0.6119226,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,CD8 | KI67,3.125,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,FOXP3,17.201503000000002,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor,45.851403000000005,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel A,On-Treatment,Tumor | KI67,22.902960999999998,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20,0.16014642,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,67.17172000000001,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,44.444445,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,64.64646499999999,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,26.8398275,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68,2.4231128,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,92.10526300000001,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,17.64706,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,38.655463,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,6.6666669999999995,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,CD80,20.282626,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,INOS,28.240251999999998,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,PDL1,9.897392,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor,44.729242,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,2.5020178,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20,0.17563117,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | CD80,38.095240000000004,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | INOS,9.12698425,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1,33.333334,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,5.882353,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68,4.8527807,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | CD80,28.658536,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | INOS,9.425288,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1,60.883796000000004,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,2.2988505999999997,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,CD80,7.456347000000001,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,INOS,5.466194,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,PDL1,11.4869885,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor,43.434467999999995,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel B,On-Treatment,Tumor | PDL1,3.8957621999999996,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4,14.271711000000002,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,0.9433962,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,0.06868132,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,0.16420361,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,4.79798,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,3.0303031000000002,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,11.6492696,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,0.35842294,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8,10.664557,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,9.764918999999999,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,3.0075189,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,6.0150377,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,27.397260000000003,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,65.28190000000001,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,PD1,3.8121805,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TCF1/7,6.392404999999999,NA,N,N,N
106-0002,062,CD8 LOW,Nivolumab + Ipilimumab,Head and neck cancer,Panel C,Baseline,TOX,17.666201,NA,N,N,N
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3,4.365639549999999,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3 | KI67,2.2222223,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD56,2.79170865,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8,2.260549,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8 | KI67,4.5454547,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,FOXP3,1.7766337,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor,35.8232215,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor | KI67,12.9901475,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20,1.1188812,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | CD80,9.677419,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | INOS,9.677419,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1,14.5833335,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1*INOS,3.2258064,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68,6.790946000000001,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | CD80,1.63879595,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | INOS,16.743119,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1,25.51724,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1*INOS,3.409091,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD80,0.2839296,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,INOS,26.659292,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,PDL1,7.328244000000001,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor,19.601542,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor | PDL1,0.41542815,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4,20.6333,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1,8.2051285,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.4588859,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TOX,1.4475271,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TCF1/7,6.502525500000001,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TOX,5.8346838,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163,14.85884,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163 | PD1,5.625,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8,5.8171745,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1,23.024948000000002,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,3.3848207500000003,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TOX,10.5809205,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TCF1/7,16.304347999999997,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TOX,33.512065,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,PD1,13.091716,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TCF1/7,12.97663,Stable Disease,N,Y,NA
106-0003,063,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TOX,8.745583,Stable Disease,N,Y,NA
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,CD3,0.073260075,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,CD3 | KI67,23.076923,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,CD56,0.193336925,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,CD8,1.2853471,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,CD8 | KI67,4,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,FOXP3,0.9125841000000001,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,Tumor,51.208794000000005,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel A,Baseline,Tumor | KI67,7.20339,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD20,0.608204165,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD20 | CD80,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD20 | INOS,62.5,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD20 | PDL1,25,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD20 | PDL1*INOS,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD68,0.8733625,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD68 | CD80,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD68 | INOS,5.263158,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD68 | PDL1,9.090909,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD68 | PDL1*INOS,4.5454545,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,CD80,0.26595744000000004,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,INOS,42.105263,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,PDL1,45.386535,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,Tumor,55.17774,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel B,Baseline,Tumor | PDL1,86.614174,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4,1.3100437,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4 | PD1,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4 | PD1*TOX,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4 | TCF1/7,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD4 | TOX,5,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD68/CD163,10.984848399999999,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD68/CD163 | PD1,0.94339625,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8,6.3081185,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8 | PD1,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8 | PD1*TOX,0,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8 | TCF1/7,3.125,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,CD8 | TOX,47.16981,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,PD1,0.15151515,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,TCF1/7,0.31695801,Stable Disease,N,Y,Y
106-0006,065,CD8 LOW,Nivolumab + Ipilimumab,Teratoma,Panel C,Baseline,TOX,36.239782,Stable Disease,N,Y,Y
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3,8.1231075,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD3 | KI67,0.505050505,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD56,0.0181290785,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8,9.371022,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,CD8 | KI67,0.3968254,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,FOXP3,0.30364373,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor,37.856084,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,Baseline,Tumor | KI67,5.1543975,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD3,16.013241,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD3 | KI67,7.04472,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD56,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD8,7.99436715,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,CD8 | KI67,0.295858,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,FOXP3,0.33765056,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,Tumor,35.2559885,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel A,On-Treatment,Tumor | KI67,24.103189500000003,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20,1.9607843999999999,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | CD80,10.384615499999999,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | INOS,0.48076925000000004,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1,40,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68,3.1408305999999997,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | CD80,6.0606062000000005,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1,69.69697000000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,CD80,25.490197999999996,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,INOS,0.23719165,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,PDL1,28.08349,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor,32.432430000000004,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,Baseline,Tumor | PDL1,23.511904,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20,3.6999999999999997,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | CD80,4.8780486,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | INOS,7.317073000000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | PDL1,47.368421999999995,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68,3.7371133,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | CD80,3.7037037500000003,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | INOS,6.896552,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | PDL1,61.538464000000005,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,CD80,24.7,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,INOS,5.7,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,PDL1,23.71134,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,Tumor,33.7,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel B,On-Treatment,Tumor | PDL1,31.157269999999997,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4,6.875000000000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1,3.125,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.4134855499999999,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | PD1*TOX,1.5763547,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TCF1/7,16.513762,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD4 | TOX,6.61157,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163,24.670865,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD68/CD163 | PD1,7.656612,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8,10.7283466,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1,0.573387475,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.09842519999999999,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | PD1*TOX,0.99316285,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TCF1/7,1.25,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,CD8 | TOX,64.220184,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,PD1,3.6937542,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TCF1/7,1.9706924000000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,Baseline,TOX,16.357205999999998,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4,10.276667,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1,49.6211605,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.28458496,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | PD1*TOX,0.635234335,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | TCF1/7,9.8531902,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD4 | TOX,4.1360813499999995,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD68/CD163,13.245714,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD68/CD163 | PD1,74.39842200000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8,1.6649191500000002,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1,10.033167500000001,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | PD1*TOX,3.34438915,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | TCF1/7,2.5,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,CD8 | TOX,49.850745,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,PD1,18.050355500000002,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,TCF1/7,7.38573175,Progressive Disease,N,N,N
106-0008,066,CD8 LOW,Nivolumab + Ipilimumab,Colorectal cancer,Panel C,On-Treatment,TOX,8.027705,Progressive Disease,N,N,N
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3,2.0242758500000004,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD3 | KI67,2.7027028,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD56,6.04932,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8,1.21916491,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,CD8 | KI67,5.65476215,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,FOXP3,1.067941815,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor,27.3957655,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel A,Baseline,Tumor | KI67,0.735804075,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20,0.22684283500000002,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | CD80,39.583335,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | INOS,16.666666499999998,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1,19.4444445,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD20 | PDL1*INOS,8.3333335,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68,2.8366631499999997,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | CD80,4.6212243,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | INOS,15.9011913,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1,33.9510495,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD68 | PDL1*INOS,2.2308477,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,CD80,1.5031279,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,INOS,9.9880555,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,PDL1,29.833461,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor,20.060951000000003,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel B,Baseline,Tumor | PDL1,12.958579,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4,17.679945,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1,3.73444,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TCF1/7,1.9323671,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | PD1*TOX,1.1485018999999999,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TCF1/7,3.8262403000000003,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD4 | TOX,1.5747876500000002,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163,17.44312,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD68/CD163 | PD1,2.5210084,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8,11.152882,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1,25,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TCF1/7,1.47392295,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | PD1*TOX,9.728507,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TCF1/7,3.25396845,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,CD8 | TOX,58.48214,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,PD1,19.300106,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TCF1/7,2.9661017000000003,Stable Disease,N,N,NA
106-0009,067,CD8 LOW,Nivolumab + Ipilimumab,Sarcoma,Panel C,Baseline,TOX,17.353199999999998,Stable Disease,N,N,NA
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3,18.5785525,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD3 | KI67,15.3801585,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD56,0.05381304,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8,3.79479585,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,CD8 | KI67,2.6936025999999997,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,FOXP3,0.07770007999999999,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor,23.1945835,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,Baseline,Tumor | KI67,13.8923023,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3,30.0496405,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD3 | KI67,2.6709557,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD56,2.67330699,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8,20.70359725,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,CD8 | KI67,2.5868971999999997,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,FOXP3,3.9482156,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor,6.940858500000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel A,On-Treatment,Tumor | KI67,12.592759849999998,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20,8.116386,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | CD80,5.7971016,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | INOS,3.3898304999999995,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1,14.492753,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.6976744,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68,6.537634000000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | CD80,5.9210528,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | INOS,6.0762165,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1,66.03774,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD68 | PDL1*INOS,2.631579,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,CD80,11.972469,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,INOS,11.053763,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,PDL1,14.712420000000002,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor,46.860644,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,Baseline,Tumor | PDL1,1.4611872,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20,15.045032149999999,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | CD80,3.2075866250000002,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | INOS,11.41653825,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1,20.965716,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD20 | PDL1*INOS,1.96678345,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68,3.861177625,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | CD80,28.256593149999997,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | INOS,13.784603375,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1,52.07003925000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD68 | PDL1*INOS,4.94519075,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,CD80,8.384607200000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,INOS,21.49539925,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,PDL1,18.416807,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor,30.368693500000003,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel B,On-Treatment,Tumor | PDL1,14.846365749999999,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4,7.8013900000000005,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1,7.8439492,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.7857143999999998,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | PD1*TOX,4.496294,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TCF1/7,33.9375555,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD4 | TOX,23.0076605,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163,16.816187,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD68/CD163 | PD1,2.7789821,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8,9.53101125,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1,2.41306875,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.2561121875,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | PD1*TOX,1.4148117999999998,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TCF1/7,15.0027665,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,CD8 | TOX,14.624734,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,PD1,4.6463535,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TCF1/7,7.360738300000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,Baseline,TOX,10.608314499999999,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4,14.802589000000001,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1,6.596534525,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TCF1/7,1.092719675,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | PD1*TOX,2.5865935,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TCF1/7,20.53249225,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD4 | TOX,16.89724025,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163,15.616794999999998,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD68/CD163 | PD1,5.562365799999999,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8,16.88921775,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1,9.242210725,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TCF1/7,1.537796525,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | PD1*TOX,5.90333215,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TCF1/7,17.66493035,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,CD8 | TOX,21.607426750000002,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,PD1,9.72592465,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TCF1/7,9.22540685,Partial Response,Y,Y,Y
106-0010,068,CD8 LOW,Nivolumab + Ipilimumab,Ovarian cancer,Panel C,On-Treatment,TOX,12.7703195,Partial Response,Y,Y,Y
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD3,3.6630040000000004,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD3 | KI67,7.5,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD56,1.7399267999999999,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD8,5.1282052,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,CD8 | KI67,5.357143000000001,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,FOXP3,3.754579,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,Tumor,39.468863999999996,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel A,Baseline,Tumor | KI67,0.9280742,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4,21.668264,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1,1.7699115,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | PD1*TOX,0.44247786999999994,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | TCF1/7,5.309734499999999,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD4 | TOX,0.88495575,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD68/CD163,16.778524,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD68/CD163 | PD1,0,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8,4.2186003,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1,9.090909,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1*TCF1/7,0,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | PD1*TOX,9.090909,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | TCF1/7,11.363637,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,CD8 | TOX,18.181818999999997,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,PD1,0.9587727500000001,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,TCF1/7,2.9721957,Progressive Disease,N,N,NA
106-0012,069,CD8 LOW,Nivolumab + Ipilimumab,Cervix cancer metastatic,Panel C,Baseline,TOX,5.848514,Progressive Disease,N,N,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,CD3,6.48278965,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,CD3 | KI67,7.765779,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,CD56,0.43370986499999997,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,CD8,0.10237737,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,CD8 | KI67,5.5555555,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,FOXP3,1.6289259,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,Tumor,14.4984545,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel A,Baseline,Tumor | KI67,45.2640565,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD20,3.9758126999999996,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD20 | CD80,13.071895999999999,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD20 | INOS,0,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD20 | PDL1,50,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD20 | PDL1*INOS,0,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD68,4.232804,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD68 | CD80,20.899472,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD68 | INOS,0.55245535,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD68 | PDL1,39.86014,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD68 | PDL1*INOS,0.13227513,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,CD80,24.558304,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,INOS,0.37792895,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,PDL1,20.463522,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,Tumor,26.225644,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel B,Baseline,Tumor | PDL1,17.463978,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4,12.150434,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4 | PD1,8.139535,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4 | PD1*TCF1/7,2.4742937,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4 | PD1*TOX,1.1154883,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4 | TCF1/7,38.554215,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD4 | TOX,4.3549044,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD68/CD163,12.817797,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD68/CD163 | PD1,7.017544000000001,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8,9.257266,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8 | PD1,7.526882,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8 | PD1*TCF1/7,1.1363637,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8 | PD1*TOX,1.7699115,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8 | TCF1/7,25.159237,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,CD8 | TOX,4.1401275,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,PD1,6.574965000000001,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,TCF1/7,14.954337,Partial Response,Y,Y,NA
107-0001,070,CD8 LOW,Nivolumab + Ipilimumab,Neuroendocrine carcinoma of the skin,Panel C,Baseline,TOX,28.292122,Partial Response,Y,Y,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD20,9.944294,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD20 | CD80,5.4782551,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD20 | INOS,0.8135967,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD20 | PDL1,30.849199,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD20 | PDL1*INOS,0.081876115,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD68,4.414933,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD68 | CD80,26.010036999999997,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD68 | INOS,0.608031675,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD68 | PDL1,33.710406500000005,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD68 | PDL1*INOS,0.22026429999999997,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,CD80,8.90607,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,INOS,5.3209900999999995,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,PDL1,14.651693999999999,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,Tumor,21.705275999999998,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel B,Baseline,Tumor | PDL1,8.670238000000001,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4,3.4782607,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4 | PD1,21.145375,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,1.2468827999999998,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4 | PD1*TOX,2.202643,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4 | TCF1/7,4.6511628,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD4 | TOX,6.25,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD68/CD163,6.110684200000001,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD68/CD163 | PD1,3.710575,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8,11.974248999999999,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8 | PD1,15.384616000000001,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,0.625,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8 | PD1*TOX,3.0898876,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8 | TCF1/7,0.7633588,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,CD8 | TOX,28.315413,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,PD1,12.384167999999999,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,TCF1/7,0.6131919,Stable Disease,N,N,NA
107-0003,071,CD8 LOW,Nivolumab + Ipilimumab,Gastric cancer,Panel C,Baseline,TOX,13.700904,Stable Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3,7.145757,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD3 | KI67,2.2727273,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD56,2.165381,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8,16.632832999999998,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,CD8 | KI67,3.2546785000000003,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,FOXP3,2.0029774,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor,32.034105000000004,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel A,Baseline,Tumor | KI67,27.46092,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20,2.4937759,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | CD80,10.482135,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | INOS,1.2196872,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1,12.945425,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD20 | PDL1*INOS,0,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68,10.1559525,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | CD80,26.405761,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | INOS,0,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1,42.294747,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD68 | PDL1*INOS,0,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,CD80,11.73823225,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,INOS,2.29107275,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,PDL1,15.353977,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor,11.907447000000001,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel B,Baseline,Tumor | PDL1,6.9128307499999995,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4,6.81928765,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1,14.3421795,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TCF1/7,3.9525689999999996,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | PD1*TOX,0.64612948,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TCF1/7,9.6837945,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD4 | TOX,1.1010728600000002,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163,9.8849613,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD68/CD163 | PD1,9.429319750000001,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8,16.7082665,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1,49.054901,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TCF1/7,3.4254901999999996,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | PD1*TOX,16.778431500000003,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TCF1/7,5.16872485,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,CD8 | TOX,21.8,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,PD1,26.260235,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TCF1/7,6.29818975,Progressive Disease,N,N,NA
107-0007,079,CD8 HIGH,Nivolumab,Head and neck cancer,Panel C,Baseline,TOX,8.3513385,Progressive Disease,N,N,NA
